



Cite this: *Biomater. Sci.*, 2025, **13**, 1871

Control and interplay of scaffold–biomolecule interactions applied to cartilage tissue engineering

Silouane Dupuy,^{†a,c} Jérémy Salvador,^{†a,b,c} Marie Morille,^{†a} Danièle Noël^c and Emmanuel Belamie^{†a,b}

Cartilage tissue engineering based on the combination of biomaterials, adult or stem cells and bioactive factors is a challenging approach for regenerative medicine with the aim of achieving the formation of a functional neotissue stable in the long term. Various 3D scaffolds have been developed to mimic the extracellular matrix environment and promote cartilage repair. In addition, bioactive factors have been extensively employed to induce and maintain the cartilage phenotype. However, the spatiotemporal control of bioactive factor release remains critical for maximizing the regenerative potential of multipotent cells, such as mesenchymal stromal cells (MSCs), and achieving efficient chondrogenesis and sustained tissue homeostasis, which are essential for the repair of hyaline cartilage. Despite advances, the effective delivery of bioactive factors is limited by challenges such as insufficient retention at the site of injury and the loss of therapeutic efficacy due to uncontrolled drug release. These limitations have prompted research on biomolecule–scaffold interactions to develop advanced delivery systems that provide sustained release and controlled bioavailability of biological factors, thereby improving therapeutic outcomes. This review focuses specifically on biomaterials (natural, hybrid and synthetic) and biomolecules (molecules, proteins, nucleic acids) of interest for cartilage engineering. Herein, we review in detail the approaches developed to maintain the biomolecules in scaffolds and control their release, based on their chemical nature and structure, through steric, non-covalent and/or covalent interactions, with a view to their application in cartilage repair.

Received 9th January 2025,
Accepted 18th February 2025

DOI: 10.1039/d5bm00049a

rsc.li/biomaterials-science

1. Introduction

Articular cartilage lesions can significantly compromise a patient's quality of life due to pain and functional disability and represent a heavy burden for the healthcare economy worldwide. Joint injuries have many possible origins including degenerative diseases and traumatic events. Due to its avascular nature and low chondrocyte to extracellular matrix (ECM) ratio, damaged cartilage has a limited self-healing capability.^{1,2} Surgical techniques such as microfracture, implantation of autologous chondrocytes or mosaicplasty attempt to repair damaged cartilage. However, current methods do not enable optimal biophysical properties to be achieved; this results in accelerated matrix degradation and generally poor tissue quality in the long-term.³ Tissue engineering (TE) appears to be a promising solution to restore the structure and function of articular cartilage.^{4,5} It relies on the

association of at least three different elements: cells, a supporting scaffold and biological factors.⁶ The ultimate objective of cartilage engineering is to generate a fully functional tissue produced by chondrocytes, the only mature cellular component of cartilage capable of secreting the ECM specific to hyaline cartilage.^{7,8}

Initial TE strategies have used chondrocytes combined with biofactors and a 3-dimensional construct to avoid chondrocyte dedifferentiation during the amplification phase *in vitro*.^{9,10} Besides, mesenchymal stromal cells (MSCs) are of particular interest owing to their ability to differentiate into chondrocytes under appropriate conditions.^{11,12} MSCs can be obtained from different sources including bone marrow, umbilical cords, adipose tissue and synovial membrane.^{13,14} However, bone marrow-derived MSCs represent the most promising source of MSCs used for cartilage engineering because of their superior chondrogenic potential.^{15,16} MSC-based therapies for cartilage engineering require the use of chondro-inductive biofactors including growth factors (GFs), peptides, or genetic material to help control or enhance cell differentiation and maintain the mature chondrocyte state, hence promoting cartilage repair. These factors differ in their mechanisms of action but also in their functions during the process of cartilage repair. It is

^aICGM, University of Montpellier, CNRS, ENSCM, Montpellier, France.

E-mail: Emmanuel.Belamie@ephe.psl.eu

^bEPHE, PSL Research University, 75014 Paris, France

^cIRMB, University of Montpellier, INSERM, Montpellier, France

[†]Both authors contributed equally.



therefore important to precisely control the kinetics of action of these biomolecules to avoid unwanted adverse effects. For these reasons, controlled levels and spatio-temporal release of these molecules are essential for promoting the formation of high-quality cartilage matrix, with the required biomechanical properties. To avoid repeated injections of biomolecules during the cartilage regeneration process, much work has been done to incorporate biomolecules into constructs and control their delivery to resident or implanted cells.

The physical and biochemical properties of scaffolds are critical for the success of cartilage repair. A biomaterial has to be biocompatible, biofunctional to promote cell adhesion and integration into the host tissue, and biodegradable. Scaffolds should also have appropriate biomechanical properties to withstand external forces resulting from joint motion. Therefore, the architecture of the scaffold plays a key role in maintaining its stability while allowing cell impregnation, cell–cell interactions and free circulation of nutrients and cell waste.⁵ Obviously, the chemical nature of the material forming the scaffold has a significant impact on the above properties.

In this article, we first provide an overview of the options for careful selection of the appropriate scaffold for cartilage TE. In the next part, we present the different biofactors currently used for cartilage TE and their regulatory role in both the differentiation of MSCs towards chondrocytes and the secretion of cartilage ECM by chondrocytes. Finally, we discuss the strategies used to functionalize scaffolds with biofactors and evaluate the impact of different approaches for the release kinetics of biofactors and their effects on chondrogenesis.

II. Scaffolds for cartilage tissue engineering: requirements and elaboration

II.1. Criteria

In the field of cartilage TE, scaffolds play a pivotal role in establishing an ideal microenvironment for promoting cell adhesion, migration, proliferation and/or differentiation. This essential function relies on several key parameters, such as appropriate architecture, controlled degradability, mechanical properties, and biocompatibility. In fact, the structural characteristics of scaffolds, including their porosity, permeability, and interconnectivity, exert a significant influence over the complex process of articular cartilage formation and subsequent tissue regeneration.^{17,18} Overall, the scaffold architecture must enable cell attachment and migration onto the scaffold while ensuring appropriate interconnectivity.¹⁹ Since scaffolds act as temporary supports for tissue development, their controlled degradation is critical for the effective formation and integration of newly generated cartilage tissue within the surrounding endogenous tissue. It is also essential that the by-products released during the degradation process are non-toxic and easily eliminated from the body.²⁰ Ideally, scaffolds should exhibit intrinsic mechanical properties

similar to those of the native cartilage tissue such as tensile strength, toughness and stiffness. These parameters are important for promoting integration and supporting continued tissue development after scaffold implantation into the knee joint.²¹

II.2. Materials

Materials used for cartilage TE obviously must be biocompatible and meet specific requirements of the target application. Numerous reviews have thoroughly examined the diverse compositions, structures, fabrication techniques, and characteristics of existing biomaterials.^{22–25}

Briefly, biomaterials can include either natural or synthetic polymers as well as hybrid materials combining both (Table 1). Natural polymers such as collagen,^{26,27} gelatin,^{28,29} hyaluronic acid (HA),^{30,31} chitosan (CH),^{32,33} chondroitin sulfate (CS),^{34,35} fibrin³⁶ and alginate^{37,38} are commonly employed in fabricating scaffolds for cartilage repair. Originating from natural sources, these materials exhibit high biocompatibility, bioactivity and possess properties close to those of native tissues, making them suitable candidates. Unfortunately, most natural materials exhibit rapid degradation, which may compromise scaffold integrity. Extracted and processed biopolymers also exhibit limited mechanical strength, which may hinder their ability to support cells and promote tissue repair. Moreover, processing natural polymers into scaffolds may be challenging due to their susceptibility to changes during processing, such as chain scission or protein denaturation.⁵

On the other hand, synthetic polymers have emerged as promising alternatives in TE, due to their tunable properties. Key synthetic polymers include polylactic acid (PLA),^{39–42} polyglycolic acid (PGA),⁴³ poly-lactic-co-glycolic acid (PLGA),^{44,45} polycaprolactone (PCL)^{46,47} and polyethylene glycol (PEG).^{48,49} The chemical composition and structure of synthetic polymers make them scaffolds with highly customizable properties. In fact, they can be tailored to exhibit specific mechanical, physical and chemical properties such as stiffness, porosity, and degradation rate in order to meet the requirements of cartilage tissue repair. However, synthetic materials also exhibit some drawbacks, notably the lack of inherent bioactivity, which hinders cell adhesion, proliferation, and differentiation. Tissue integration and functionality are consequently affected because the biomaterial does not fully replicate the biochemical and biomechanical properties and cues of native cartilage tissue.⁵⁰ Moreover, harmful acidic degradation products may compromise biocompatibility and trigger an inflammatory response.²⁰

Obviously, the chemical nature of the material forming the supporting scaffold has a significant impact on its properties, and notably its ability to incorporate bioactive compounds. For instance, hydrophobic aliphatic polyesters (PLA, PGA, PLGA, PCL...) can be processed into porous scaffolds but with poorly hydrated solid walls, while hydrophilic polymers (collagen, gelatin, hyaluronic acid, PEG...) can form highly swollen hydrogels. Of note, the biophysical characteristics of the scaffolds



Table 1 Main materials used for cartilage tissue engineering

| | Materials | Advantages | Disadvantages | Ref. |
|-----------|----------------------|---|--|-----------|
| Natural | Collagen | Biocompatibility Biodegradability Low immunogenicity Cell adhesion proliferation and differentiation | Low mechanical strength Low solubility Rapid biodegradation Difficult to handle | 26 and 27 |
| | Gelatin | Biocompatibility Biodegradability Accessibility | Low mechanical strength Stability Poor mechanism properties Low solubility | 28 and 29 |
| | Hyaluronic acid (HA) | Biocompatibility Biodegradability Easy chemical modification Bioactivity | Cost Low mechanical strength Fast degradation | 30 and 31 |
| | Chitosan (CH) | Biocompatibility Biodegradability Cell adhesion, proliferation and differentiation Anti-microbial activity | Low mechanical strength Low solubility | 32 and 33 |
| | Fibrin | Biocompatibility Inexpensive Accessibility Cell adhesion and proliferation | Cost Low mechanical strength Fast degradation | 36 |
| | Alginate | Biocompatibility Biodegradability Accessibility Bioactivity | Low mechanical strength Limited strength Difficult to handle | 37 and 38 |
| Synthetic | PLA | Biocompatibility Thermostability Thermoplasticity Degradability | Poor cell adhesion | 39–42 |
| | PGA | Availability Easy processing Biocompatibility | Acid release upon degradation Poor cell adhesion Fast degradation Mechanical properties | 43 |
| | PLGA | Mechanical properties Controlled degradability | Acid release upon degradation | 44 and 45 |
| | PCL | Mechanical properties Biocompatibility Thermoplasticity Biodegradability | Poor cell adhesion Poor hydrophobicity | 46 and 47 |
| | PEG | Biocompatibility Biodegradability | Poor cell adhesion | 48 and 49 |

resulting from their chemical composition can also be engineered to enhance or direct MSC differentiation. The roles of substrate features such as mechanical properties, porosity or topology have been reviewed elsewhere^{51,52} and are addressed in the present article only when directly related to biomolecule interactions with the scaffold and their release profiles.

II.3. Techniques

The desired scaffold architecture, mechanical properties and shapes can be achieved by selecting the appropriate scaffold fabrication method. A variety of fabrication methods enable the production of scaffolds in the form of three-dimensional membranes, hydrogels, microspheres, sponges, or their combinations, thereby providing versatility to meet the diverse requirements of cartilage TE.⁵³ Hydrogels, in particular, have attracted considerable attention as scaffolds for cartilage TE due to their structural and functional resemblance to the ECM.⁵⁴ Hydrogel formation involves the development of hydrophilic polymer networks through chemical cross-linking, physical gelation, or self-assembly processes. These networks

are capable of absorbing water and swelling in aqueous solutions; this promotes the attachment, migration, differentiation, and proliferation of cells while effectively delivering growth factors and creating an appropriate microenvironment for nutrients.^{55,56} Scaffold fabrication techniques for cartilage TE include conventional and rapid prototyping (RP) methods, which have been described in many reviews (Table 2).^{57,58}

Conventional methods for scaffold fabrication are often constrained by limitations in compatibility and repeatability, and frequently rely on manual intervention, making them unsuitable for large-scale application. Among these methods, phase inversion is commonly employed for membrane preparation, and usually divided into thermally induced phase separation (TIPS) and non-solvent induced phase separation (NIPS). TIPS utilizes temperature manipulation in liquid-liquid or liquid-solid systems to achieve membranes with varied porosities, whereas NIPS involves immersing a polymer solution in a non-solvent solution, resulting in membranes with different porosities and pore sizes.⁵⁹ The TIPS technique has been specifically applied to fabricate PLLA scaffolds with



Table 2 Main scaffold preparation techniques for cartilage tissue engineering

| Techniques | Advantages | Disadvantage | Ref. |
|---------------------------------------|--|--|-------------|
| Phase inversion | Versatility Compatibility Repeatability | Lack of pore interconnectivity control Processing conditions Applicability | 60 and 278 |
| Solvent casting and particle leaching | Easy processing Adjustable porosity | Cytotoxic solvent Low mechanical strength | 279 and 280 |
| Gas foaming | Inexpensive Porosity control | Pore size distribution Lack of pore interconnectivity control | 281 |
| Electrospinning | Large-scale production possibilities Repeatability Easy process | Limited range of polymers | 282–284 |
| Freeze-drying | Adjustable porosity and structure Large interconnectivity of the porous structure | Energy intensive and time consuming Cytotoxic solvents | 285 |
| 3D bioprinting | High resolution High throughput capability Reproducibility Easy to use | Inkjet viscosity | 286–288 |

finely tuned pore dimensions, mimicking natural conditions conducive to efficient chondrogenesis.⁶⁰ Additional techniques, such as freeze-drying, can also improve scaffold porosity and pore size. Freeze-drying, or lyophilization, involves freezing polymer solutions followed by solvent sublimation under vacuum, producing scaffolds with interconnected porous structures.⁶¹ Electrospinning is another widely used method due to its simplicity, rapidity, cost-effectiveness, and ability to generate nonwoven scaffolds with high porosity and interconnectivity.⁶² Electrospun nanofiber-based scaffolds are expected to be good candidates for osteochondral and cartilage repair but their outcome is mostly limited by spinnability issues of the biomolecule-containing aqueous solutions. Coaxial electrospinning offers a promising alternative, as only the shell solution, producing the outer part of the fibre, must exhibit good spinnability. In this technique, drugs, proteins, or other bioactive substances are incorporated into the fibre core through coaxial flow, resulting in a core–sheath structure. These biphasic nanofibers, capable of controlled biomolecule release, have been extensively studied for biomedical applications, including osteochondral regeneration.^{63–65} However, despite its effectiveness, it often lacks the ability to precisely control scaffold architecture and mechanical properties. Nevertheless, developments in biomaterial design have shown the potential to overcome these limitations. For instance, electrospun scaffolds combining gelatin–chondroitin sulphate nanofibers with mechanically robust polycaprolactone (PCL) have been shown to successfully promote chondrogenesis without the need for differentiation media.⁶⁶

In contrast, advanced RP techniques, such as 3D printing, including 3D bioprinting and selective laser sintering, allow for intricate scaffold design with precise spatial control, enabling the formation of complex structures layer by layer (LBL).⁶⁷ 3D bioprinting appears to be a promising approach for inserting biomolecules at desired 3D locations to build a scaffold with spatiotemporally controlled biomolecule release properties.^{68–70} The modification of scaffold characteristics depends on various factors such as the ink type, and other

parameters such as the printing temperature, needle size, layer density, and extrusion rate.^{67,71,72}

Additionally, the fabrication process must meet several critical criteria beyond its functionality, such as cost-effectiveness and scalability. Developing scalable manufacturing processes up to good manufacturing practice (GMP) standards is also crucial for ensuring the successful translation of TE strategies into clinical practice.

III. Biomolecules for cartilage tissue engineering

Several biomolecules, including but not restricted to, growth factors, peptides, genetic material and small molecules, are described to mediate cellular proliferation, migration, and differentiation. These factors can interact with target cells and trigger a series of specific cellular activities. Here, we focus on the main biomolecules involved in the development of cartilage and describe their role in regulating the processes of chondrogenesis and cartilage homeostasis (Table 3).

III.1 Small molecules

III.1.1. Kartogenin (KGN). Kartogenin (KGN) is a non-toxic and stable small molecule reported to promote collagen synthesis and enhance the chondrogenic differentiation of MSCs. During MSC chondrogenesis, KGN frees CBF β , which then binds to the transcription factor RUNX1. This complex plays a crucial role in initiating the transcription of genes associated with cartilage ECM production.⁷³ Together with other advantages, such as low immunogenicity,⁷⁴ KGN shows significant promise for promoting cartilage regeneration.⁷⁵ Furthermore, the absence of the induction of genes related to hypertrophy and calcification was observed when KGN was applied to MSCs or chondrocytes.^{73,74} Although dosage and duration time still need to be optimized, several studies have reported the beneficial effect of a continuous supply of KGN being released from a scaffold on cartilage repair.^{76–79} For example,



Table 3 Main biomolecules used for cartilage engineering and their effect on chondrogenic differentiation

| Biomolecules | Type of biomolecule | Desired effect on MSC chondrogenic differentiation | Adverse effects on differentiation | Ref. |
|--------------------------|---------------------|---|---|--|
| Kartogenin | Small molecule | Induces chondrogenesis/enhances matrix production | — | 74, 76 and 289–293 |
| Curcumin | Small molecule | Induces chondrogenesis | — | 85 and 86 |
| Glucosamine | Small molecule | Induces chondrogenesis | — | 87 and 88 |
| Icariin | Small molecule | Induces chondrogenesis/inhibits hypertrophic differentiation | — | 89–91 |
| Melatonin | Small molecule | Induces chondrogenesis | — | 96 and 98 |
| Ascorbic acid | Small molecule | Chondrocyte growth/enhances cartilage matrix production | — | 101 and 102 |
| TGF- β 1 and 3 | Growth factor | Enhances proliferation/inhibits migration/induces differentiation/maintains articular chondrocytes | Promotes hypertrophic differentiation | 104, 105, 253, 262, 275, 289 and 294–298 |
| BMP-2 | Growth factor | Enhances matrix production | Promotes hypertrophic differentiation Induces osteogenic differentiation | 299 and 300 |
| BMP-4 | Growth factor | Induces chondrogenesis/maintains chondrocyte phenotype/enhances matrix production/inhibits hypertrophic differentiation | — | 115 |
| BMP-6 | Growth factor | Induces chondrogenesis/enhances matrix production/inhibits hypertrophic differentiation | Promotes hypertrophic differentiation | 301 and 302 |
| BMP-7 | Growth factor | Induces chondrogenesis/enhances matrix production/inhibits hypertrophic differentiation | — | 299, 303 and 304 |
| IGF-1 | Growth factor | Induces chondrogenesis | — | 120 |
| IGF-2 | Growth factor | Primes chondrogenic differentiation | — | 122 |
| FGF-2 (bFGF) | Growth factor | Maintains chondrogenic potential/enhances matrix production | Promotes fibrocartilage formation | 126–131 |
| PDGF | Growth factor | Exerts chemotactic effects/induces proliferation/induces chondrogenesis | — | 298, 305 and 306 |
| PTHrP | Protein | Inhibits hypertrophic differentiation | — | 139–141 and 307 |
| Peptides | Amino acid sequence | Recruit endogenous stromal cells | — | 147 and 150 |
| Nucleic acid | miRNA siRNA | Potential interest for all cartilage engineering steps | — | 153, 158, 159, 308 and 309 |
| Hypoxia-mimicking agents | Small molecules | Induces chondrogenesis/inhibits hypertrophic differentiation | — | 169, 170 and 310 |

KGN-encapsulated PLGA microspheres enable the sustained release of KGN, improving retention and enhancing therapeutic efficacy.^{79,80}

III.1.2 Curcumin. Curcumin is a yellow polyphenol pigment isolated from *Curcuma longa* (turmeric). It has been studied for its antioxidant and anti-inflammatory effects.^{81–83} Recently, high viability and phenotype maintenance of chondrocytes cultured in curcumin-containing silk scaffolds suggested great potential for cartilage engineering.⁸⁴ Although the role of curcumin in chondrogenic differentiation is not yet fully understood, it might indirectly induce the chondrogenic differentiation of MSCs thanks to its anti-apoptotic capacity *via* caspase-3 inhibition and its anti-inflammatory function on prostaglandins such as PGE2.^{85,86}

III.1.3 Glucosamine. Glucosamine is a naturally occurring amino monosaccharide found in connective and cartilage tissues as a component of glycosaminoglycans (GAGs). It helps maintain the strength, flexibility, and elasticity of these tissues and has been widely studied as a stimulator of chondrocyte metabolism for osteoarthritis treatment.⁸⁷ The mechanism underlying its chondroprotective action remains incompletely understood, but it is known to modulate GAG production, par-

ticularly hyaluronic acid (HA) and keratan sulfate (KS), in synovial cells and chondrocytes.⁸⁸

III.1.4 Icariin. Icariin, a prevalent flavonoid glycoside, is the principal pharmacological constituent of *Herba Epimedii* (HEP). HEP is commonly utilized as a traditional Chinese herbal remedy, with a history of extensive use in China, Japan, and Korea where it is valued for its anti-rheumatoid, tonic, and aphrodisiac properties.⁸⁹ Different studies suggested the relevance of using icariin as an effective growth factor for cartilage TE by promoting chondrogenic differentiation and reducing hypertrophic markers.^{90–92} It has been shown that icariin upregulates parathyroid hormone-related protein (PTHrP) and downregulates the expression of Indian hedgehog homolog (IHH),⁹³ thereby reducing cartilage degradation and destruction.⁹⁴

III.1.5 Melatonin (MLT). Melatonin (MLT) is a ubiquitous molecule in nature. MLT has been shown to play several biological roles, including the promotion of hMSC chondrogenic differentiation^{95,96} and chondrocyte function.^{97,98} This process is mediated through MLT membrane receptors 1 and 2, leading to BMP-2 expression and subsequent Smad1/5/8 phosphorylation, which are crucial steps in stem cell differen-



tiation.⁹⁶ MLT has also been shown to upregulate miR-526b-3p and miR-590-5p, which target Smad7, enhancing Smad1 phosphorylation and promoting the differentiation of hMSCs.⁹⁹ MLT not only promotes cartilage formation but also prevents apoptosis and calcification of chondrocytes. MLT induces autophagy in chondrocytes by increasing Sirt1 expression and activity, which in turn inhibits the expression of pro-apoptotic proteins (Bax and cleaved caspase-3) and promotes anti-apoptotic proteins (Bcl-2), resulting in reduced chondrocyte apoptosis.¹⁰⁰

III.1.6 Ascorbic acid. Ascorbic acid, also known as vitamin C, plays a pivotal role in promoting chondrocyte proliferation and inducing chondrogenesis.¹⁰¹ Ascorbic acid acts as a cofactor in the formation of hydroxyproline and hydroxylysine within the collagen molecule thereby enhancing its stability, and promoting its synthesis.¹⁰² Many studies have demonstrated the effect of ascorbic acid on chondrocyte growth and ECM secretion, as exemplified by a significant increase of type II collagen secretion concomitant with matrix metalloproteinase-13 decrease.¹⁰³

III.2. Growth factors and other proteins

III.2.1. Transforming growth factor- β (TGF- β). Transforming growth factor- β (TGF- β) plays critical roles in regulating MSC differentiation from early to terminal stages, including condensation, proliferation, commitment, maturation and terminal differentiation.^{104–106} The TGF- β family includes TGF- β 1, 2, and 3, activins (A and B), inhibins (A and B), bone morphogenetic proteins (BMP-1 to 20), and growth differentiation factors (GDFs) including nodal, myostatin (GDF-8), and mullerian-inhibiting substance (MIS). TGF- β members bind serine/threonine kinase type II receptors, which activate type I receptors anchored in the cell membrane through phosphorylation. The resulting signal transduction to the nucleus *via* R-Smads 2 or 3 modulates the responsive genes (Fig. 1).^{107,108} TGF- β 1, 2, and 3 are potent stimulators of proliferation and the metabolism of chondrocytes through the secretion of cartilage ECM components including proteoglycans and type II collagen.¹⁰⁹ Currently, TGF- β 3 serves as a common and potent inductive molecule incorporated into various scaffolds to stimulate the chondrogenic differentiation of MSCs as it is considered to have a greater chondrogenic effect than TGF- β 1.^{44,110,111}

III.2.2. Bone morphogenetic proteins (BMPs). Bone morphogenetic proteins (BMPs) are members of the TGF- β superfamily. They can induce the differentiation of MSCs into chondrocytes and promote the synthesis of cartilage ECM.¹¹³ At least 30 different BMPs have been described, of which BMP-2, BMP-4, BMP-6 and BMP-7 have been the most widely studied in the field of cartilage TE.¹¹³ The different BMP isoforms act together or sequentially at all stages of differentiation.^{113,114} For example, BMP-2 and BMP-4 induce the differentiation of MSCs into chondrocytes, but only BMP-4 may inhibit hypertrophic terminal differentiation.¹¹⁵ Indeed, over-expression of BMP-4 suppresses the formation of hypertrophic chondrocytes during the *in vitro* differentiation of murine C3H10T1/2 mesenchymal progenitor cells.¹¹⁶ In addition, a BMP-4 loaded alginate gel has shown promising results in cartilage repair.¹¹⁷

III.2.3. Insulin-like growth factor (IGF). Insulin-like growth factor (IGF) exists in two isoforms, IGF-1 and IGF-2, which have been shown to promote the proliferation of chondrocytes, and the secretion of cartilage ECM.^{118–120} More specifically, IGF-1 was shown to induce the proliferation of chondrocytes and the chondrogenic differentiation of MSCs through the IGF-1/PI3K/Akt and IGF-1/MAPK/ERK signalling pathways, whereas IGF-2 was described to enhance differentiation by priming MSCs through SOX9 regulation.^{120–122} These results suggest that both isoforms are required during the early phases of chondrogenic differentiation but IGF-1 can also act at a later stage to enhance the secretion of the ECM.^{123,124}

III.2.4. Fibroblastic growth factors (FGFs). Fibroblastic growth factors (FGFs) belong to a family of 22 highly homologous polypeptides involved in chondrocyte proliferation, joint development, and homeostasis of cartilage. Among them, FGF-2 or basic FGF (bFGF), which is recognized by its cognate receptor FGFR-1, is the most studied for its effect on chondrocytes and MSCs through multiple downstream signalling cascades, including PKC δ , NF κ B, Ras-Raf-MAPK and PI3K/Akt pathways (Fig. 1).¹²⁵ This growth factor is described for its capacity to enhance the proliferation of MSCs, to delay the loss of chondrogenic potential of MSCs, and to maintain the chondrogenic potential of chondrocytes during expansion and the differentiation of MSCs by up-regulating SOX9.^{126–128} However, other studies have demonstrated that bFGF can promote chondrocyte catabolism *via* the FGFR1/Ras/Raf/MEK1-2/ERK1-2 axis and inhibit the anabolic activity of IGF-1 and BMP-7.¹²⁹ bFGF could also induce the formation of fibrocartilage, which is a poor alternative to hyaline cartilage.^{129–131} Therefore, based on these studies, the use of bFGF in cartilage TE is questionable. Nevertheless, improved healing of osteochondral lesions has been demonstrated in rabbits using a highly porous scaffold soaked with bFGF.¹³² However, an inverse dose response was observed, which might partly explain the controversial results reported so far. These results suggest that bFGF concentration might be an essential criterion for efficient cartilage repair and highlight the need for its tightly controlled release by an optimized scaffold in order to maintain its beneficial properties.

III.2.5. Platelet-derived growth factor (PDGF). Platelet-derived growth factor (PDGF) is a dimer with a molecular weight of approximately 25 kDa. This cytokine released by platelets at injury sites promotes mesenchymal cell proliferation.¹³³ Prolonged exposure to PDGF enhances cartilage ECM production, while suppressing the progression of cells along the endochondral maturation pathway.¹³³ These observations suggest the possibility of using PDGF at the late stage of MSC differentiation to avoid hypertrophic differentiation. In addition, some isoforms, such as PDGF-BB, have an interesting chemoattractant property that could be used to retain MSCs and chondrocytes in a scaffold after *in vivo* implantation, allowing secretion of the ECM at the injury site.^{134–136}

III.2.6. Parathyroid hormone-related protein (PTHrP). Parathyroid hormone-related protein (PTHrP) is a member of the parathyroid hormone family secreted by MSCs, smooth muscle cells and some cancer cells. It is a 141 amino acid poly-






Fig. 1 Signalling pathways and proteins involved in the chondrogenic differentiation of mesenchymal stromal cells. Reproduced from ref. 112 with permission from Springer Nature, copyright 2022.

peptide, which acts as an endocrine, autocrine, paracrine, and intracrine hormone. Most of its biological functions are mediated by its amino terminus, including its effect on cartilage.^{137,138} PTHrP is largely described to promote chondrogenesis by repressing hypertrophy through the transcriptional control of Runx2 activity by the Gsa/cAMP/PKA-dependent signalling pathway (Fig. 1).^{139–142} However, PTHrP is also described to induce osteogenic differentiation of bone marrow-derived MSCs through upregulation of local factors, notably BMPs.^{143,144} In the context of MSC-based cartilage TE, PTHrP has to be precisely controlled in order to take advantage of its anti-hypertrophic function without affecting the early steps of chondrogenesis.

III.3. Peptides

More recently, the use of peptides that can induce cellular responses such as cell recruitment, tissue integration and

differentiation has been investigated in cartilage TE.^{145–147} Technological advances have reduced synthesis costs, making research and potential applications more accessible. For instance, the peptide “HAVDI” from the N-cadherin sequence mimics the cell–cell interaction signal, which is key to facilitating MSC condensation, the initial step of chondrogenesis.¹⁴⁸ This interaction enhances the chondrogenic potential of MSCs encapsulated in HA hydrogels.¹⁴⁹ Another approach relies on the use of chemoattractive peptides to recruit endogenous MSCs. Although this strategy aims to increase neotissue integration rather than cartilage engineering, it shows great potential for cartilage repair. Indeed, scaffolds prepared from porcine acellular cartilage matrix functionalized with BMHP (bone marrow homing peptide) enhanced cartilage formation in full-thickness cartilage defects of rabbits.¹⁵⁰ After a six-month period, defects were filled with neocartilage tissue that exhibited a smooth surface similar to native tissue. A similar



approach used an injectable hydrogel functionalized with KLPP peptide to facilitate the simultaneous recruitment of endogenous MSCs promoting interface integration and improving cartilage repair.¹⁴⁷

III.4. Nucleic acids

Nucleic acid-based strategies rely on the modulation of transcription factors or regulatory molecules in transfected cells *in vitro* or in endogenous cartilage tissue in *ex vivo* strategies.^{144,151,152} A better understanding of MSC biology has led to the discovery of numerous nucleic acid molecules capable of influencing the chondrogenic differentiation of MSCs, as a complementary and powerful strategy for cartilage TE.^{153–157} Due to their diversity, nucleic acid-based therapies can target the entire differentiation process, from its induction to the maintenance of the quiescent stage of chondrocytes and the inhibition of hypertrophy.^{158–160} As an example, using RNA interference (RNAi) tools, the specific suppression of anti-chondrogenic factors could represent a promising approach for MSC-based cartilage repair. Recently, the potential of siRNAs targeting the RUNX2 gene to inhibit the expression of hypertrophic markers after the chondrogenic differentiation of MSCs was demonstrated.^{155,161} A siRNA targeting sonic hedgehog (SHH) can significantly attenuate cartilage degeneration and decrease the OA score in rat models.¹⁶² Other studies have reported the potential of microRNAs (miRNAs) for regulating the expression of genes involved in cartilage synthesis and homeostasis.^{163–166} MiRNAs are short, single-stranded RNA molecules 18 to 24 nucleotides long. They function as transcriptional repressors by binding to the untranslated region (UTR) of target messenger RNA (mRNA), decreasing the expression of target genes. Over 30 miRNAs present in human joint tissue are implicated in regulating cartilage homeostasis and OA development. Among these, miR-140 has attracted considerable interest and multiple miR140 targets have been identified and described.¹⁶⁶ Notably, the inhibitory effect of miR-140 in chondrocyte hypertrophy has been shown to occur through the inhibition of histone deacetylase (HDAC)-4 and SMAD1.^{167,168}

III.5. Hypoxia-mimicking molecules

It is well recognized that the chondrogenic differentiation of MSCs can be achieved by maintaining the cells under hypoxic conditions, thus simulating the native environment of articular cartilage.¹⁶⁹ Additionally, hypoxic culture conditions have been shown to suppress the expression of markers associated with endochondral ossification through the activation of the PI3K/Akt/FoxO pathway.¹⁷⁰ Secretion of the ECM was found to be enhanced when using human articular chondrocytes pretreated with hypoxia prior to encapsulation in alginate hydrogels and implantation in a nude mouse model.¹⁷¹

Hypoxia induces the expression and stabilization of hypoxia-inducible factor-1 α (HIF-1 α), a key regulator of the hypoxic response that plays a critical role in chondrocyte

differentiation and survival *in vivo*. Under normoxia conditions, HIF-1 α is hydroxylated by prolyl-hydroxylase domain enzymes (PHDs) and the factor inhibiting HIF (FIH) hydroxylase, resulting in immediate ubiquitination and subsequent proteasomal degradation of the subunit. In a low-oxygen environment, the activities of PHDs and FIH are inhibited. HIF-1 α accumulates in cells and binds to HIF-1 β to form HIF-1, which then binds to HRE to participate in multiple signalling pathways by regulating the transcription of hundreds of genes, including those specific to cartilage. Currently, HIF signalling pathways mainly include PI3K-Akt/HIF-1 α , SENP1/HIF-1 α , HIF-1 α /BNIP3, and MAPK/HIF-1 α ¹⁷² (Fig. 1). Instead of hypoxia incubators or chambers, several hypoxia-mimetic agents have been employed to induce hypoxia. These molecules are not widely studied but their low cost and ease of use make them a promising class of potential tools for use in cartilage TE.¹⁷³

III.5.1. DMOG (dimethyloxallylglycine). DMOG (dimethyloxallylglycine) is a competitive inhibitor of hydroxylase enzymes, and its presence results in increased nuclear localization of HIF-1 α , thereby promoting chondrogenic differentiation through the increased production of type II collagen and other extracellular matrix components.¹⁷⁴ Recently, the sequential application of DMOG and PTHrP encapsulated in PLGA microspheres effectively mimicked the hypoxic microenvironment, thereby promoting chondrogenic differentiation with phenotypic stability.¹⁷⁵

III.5.2. DFO (deferroxamine). DFO (deferroxamine) is a chelating agent that is approved by the Federal Drug Administration for the treatment of excess iron.¹⁷⁶ The activity of PHD is dependent on Fe²⁺ and O₂ concentrations. Consequently, a reduction in iron concentration results in decreased HIF-1 α hydroxylation and its accumulation in cells. As a PHD inhibitor, DFO is a suitable agent for mimicking hypoxic conditions and therefore represents a promising molecule with the potential to optimize biomaterials and existing TE techniques for tissue regeneration.¹⁷⁷

III.5.3. Cobalt chloride (CoCl₂). Cobalt chloride (CoCl₂) has the capacity to impede the degradation of HIF-1 α protein, thereby inducing its accumulation and, consequently, inducing hypoxia. This characteristic is derived from the ability of Co²⁺ to inactivate FIH by substituting Fe²⁺ in the iron-binding center of the enzyme.^{178,179} CoCl₂ encapsulation into an alginate scaffold is shown to promote chondrogenesis without the use of costly growth factors.¹⁸⁰

As described above, many biomolecules (Table 3) can be used to regulate cellular activity at different stages of chondrogenesis, depending on their function or the time of application. However, most of these active molecules have short-term action due to their rapid elimination or degradation after delivery. Therefore, they must be protected before being released in a controlled manner. Scaffold engineering to precisely fine-tune the spatiotemporal release of biomolecules is therefore being investigated to better control cell behaviour and *in fine*, improve cartilage TE efficacy.¹¹³



IV. Interactions and mechanisms involved in biomolecule delivery from scaffolds

IV.1. Non-covalent interactions

As the field of cartilage TE has rapidly expanded, many three-dimensional and porous scaffolds are considered to be active biomolecule-release systems. Typically, active molecules entrapped in polymer materials are released into the surrounding medium due to the combination of diffusion of the molecule through the matrix and matrix erosion. The proportion of these two contributions depends on the nature of the polymers, the hydration level of the matrix, its porosity and interactions, specific or not, between the active compounds and the supporting materials. Regarding diffusion, in the absence of a covalent bond between the biomolecules and the matrix, the retention rates and release kinetics mostly result from weak interactions and steric hindrance (Fig. 2).

IV.1.1. Steric hindrance. Steric hindrance is a physical barrier to the diffusion of active compounds or vector particles through hydrogels. The meshes of the scaffold create a steric obstruction, which hinders the diffusion of the biomolecules

and delays their release. Steric interactions are involved when biomolecules are loaded or released by diffusion through and out of the matrix. In the case of particles used as reservoirs of biomolecules or small molecules, or in the case of vectors used to protect and deliver nucleic acids, the relevant dimensions are those of the carriers. The loading rate and delivery kinetics thus depend not only on the biomolecule or vector size but also on the chemical nature and structure of the matrix in which they are immobilized. Structural features include the morphology, density (concentration, crosslinking rate), and porous structure (tortuosity, pore size) of the scaffold. As an example, more than 95% of IGF-1 was released over a 28-day period, with gelatin microparticles cross-linked with 40 mM glutaraldehyde, while similar release values were obtained after only 6 days when using microparticles cross-linked with 10 mM glutaraldehyde.¹⁸¹

To control the release of siRNA, siRNA lipoplexes encapsulated in a gellan gum hydrogel exhibited prolonged release over 60 days, while naked siRNA was released from the hydrogel within 48 h.¹⁸² Similarly, the impact of steric interactions was evaluated in the case of siRNA nanoparticles (si-NPs) loaded in a porous biodegradable polyester-polyurethane (PUR) scaffold.¹⁸³ The si-NPs were formulated with a defined




Fig. 2 Schematic representation of possible steric interactions between active molecules and scaffolds, and their modulation to alter biomolecule release kinetics. **Biomolecule engineering:** small, unmodified (green) and large or modified biomolecules (purple) interact differently within the scaffold matrix based on their size and structure. **Scaffold engineering:** the scaffold porosity and density are tuned to control biomolecule interactions: high-density scaffolds with low porosity and small pore sizes limit diffusion, while low-density scaffolds with high porosity and large pore sizes enhance release of molecules. **Biomolecule encapsulation:** biomolecules are effectively encapsulated in (nano-)particles within the scaffold, ensuring confinement and preserving functionality.

Table 4 Main entrapment mechanisms used for the controlled release of biomolecules involved in the chondrogenic differentiation of MSCs

| Interaction type | Entrapment mechanism | Biomolecules | Ref. |
|---------------------------|-----------------------------------|---|--------------------------|
| Non-covalent interactions | Weak interactions | TGF β 1-2-3/PTHrP/bFGF/BMP-2/curcumin/chondroitin sulphate/nucleic acid | 173, 179–182 and 188–293 |
| | Steric entrapment | TGF β 1-2-3/IGF/bFGF/PTHrP/BMPs/kartogenin/chondroitin sulphate/curcumin/nucleic acid | 151–153, 156 and 164–169 |
| Covalent interactions | Crosslinking | TGF- β 1-3/BMP-2/BMP-4/kartogenin | 207–210 and 212 |
| | Photoimmobilization | BMP-2/PDGF | 95 and 217–221 |
| | Click chemistry | TGF- β 1/BMP-2 | 227–228 |
| Multi-scaffolding system | Combination of several techniques | TGF- β 1-2-3/BMP-7/kartogenin/curcumin | 237–246 and 253–255 |






Fig. 3 Sustained local delivery of siRNA from an injectable scaffold. (a) Chemical structure of polyurethane precursors. Lysine triisocyanate reacts with the –OH groups of the polyol to form urethane bonds and creates the PUR network. (b) Chemical structure of the micelle-forming, pH-responsive diblock copolymer used for siRNA packaging and intracellular delivery. The homo-2-(diethylamino)ethyl methacrylate (DMAEMA) block was designed for siRNA condensation due to the positive charge on the tertiary amines. The other block is pH-responsive and tuned for endosomal escape due to micelle destabilization and endosomolytic activity triggered by protonation of 2-propyl acrylic acid (PAA) and DMAEMA. (c) Naked siRNA is rapidly released with an initial burst of over 60% after 12 h and is entirely released after 3 days. Si-NPs exhibit slower kinetics with a burst release of less than 20% during the first 12 h, followed by sustained release reaching 80% after 21 days. The Weibull empirical model equation best-fit was determined and is overlaid here for each data set. Reproduced from ref. 183 with permission from Elsevier, copyright 2012.

charge ratio between positively charged tertiary amines on the DMAEMA block of the polymer and negatively charged phosphate groups on the siRNA backbone (Fig. 3). The diffusion and release kinetics of encapsulated siRNAs and free siRNAs were compared. The release data demonstrated cumulative release of si-NPs approaching 80% over 21 days, which was considerably slower than naked siRNAs completely released in three days. The release rates of naked and complexed siRNAs scaled with their hydrodynamic diameters and their diffusivity throughout the PUR matrix. This property is particularly useful for gene transfer strategies, since NPs preserve nucleic acid integrity and serve as a vector that enables genetic material to cross the cell membrane.^{153,184,185} Recently, we demonstrated that it was possible to obtain different siRNA diffusion profiles from a collagen hydrogel, depending on the size of the vector used.¹⁸⁶ Interestingly, the inhibition profiles of the target gene Runx2 over time was correlated with the release kinetics, and hence with the size of the siRNA vector.

IV.1.2. Scaffold degradation. One major function of scaffolds applied to cartilage TE is to provide 3D support for chondrocytes, and thus to promote ECM secretion. However, the scaffolds are not intended to stay in the joint. Ideally, they should be gradually degraded and replaced with the newly created cartilage matrix. This is why scaffolds used in cartilage TE are generally made of biodegradable materials.^{187,188} Scaffold degradation is accompanied by a reduction of steric constraints and therefore plays an important role in the release of encapsulated biomolecules (Fig. 4).

A multitude of factors can affect the rate of scaffold degradation *in vivo*, including the surrounding environment, the com-

position and structure of the biomaterial, and the physical loading to which the scaffold is subjected.^{189–191} Indeed, the degradation of a polymer scaffold involves chain cleavage processes induced for instance by hydrolysis, oxidation or photodegradation.¹⁹⁰ *In vivo*, scaffold degradation takes place in an aqueous biological environment where hydrolysis plays an important role, often promoted by enzymatic activities (proteases, esterases...). In the context of cartilage TE, the degradation of the natural polymer scaffold, comprised of collagen for instance, may be accelerated by matrix metalloproteases (MMPs) secreted by chondrocytes resulting in accelerated or triggered release of biomolecules.¹⁹² As an example, micelles containing miR-140 entrapped in MMP-sensitive microparticles composed of gelatin methacryloyl hydrogel have been developed.¹⁹³ In the presence of MMPs, complete release of miR-140 from the microparticles was achieved after 5 days, compared to more than 14 days in the absence of MMPs (Fig. 5). The authors exploited the presence of large amounts of MMPs in the OA joint capsule to degrade the scaffold, thus releasing the entrapped micelles loaded with miR-140. After *in vivo* injection, a notable reduction in osteophyte formation and OARSI score was demonstrated in a DMM-induced OA model. The group that received the micelles containing miR-140 entrapped in MMP-sensitive microparticles demonstrated the most favourable outcome with regard to GAG level, indicating optimal retention of the cartilage thickness. In addition, the expression of COL2 was the highest while MMP13 expression exhibited an inverse correlation among this group. These findings collectively suggest that these MMP-sensitive microparticles have the potential to delay the degeneration of articular cartilage and the progression of OA.






Fig. 4 Schematic representation of biomolecule delivery by scaffold degradation. **Fragmentation**: the scaffold breaks into smaller fragments, releasing encapsulated molecules into the surrounding environment. **Triggered degradation**: enzymatic activity selectively degrades specific regions of the scaffold, facilitating the release of biomolecules. **Erosion**: the scaffold undergoes gradual thinning and complete degradation, resulting in the sustained release of the remaining embedded biomolecules.




Fig. 5 MMPs triggered mir-140 release for local treatment of osteoarthritis. (a) Synthesis of the multifunctional gene vector: arginine (A), histidine (H), and phenylalanine (P)-modified generation 5 (G5) polyamidoamine (G5-AHP), G5-AHP/miR-140 and G5-AHP/miR-140 after immobilization in gene-hydrogel microspheres (MS@G5-AHP/miR-140). (b) Cumulative release curve of MS@G5-AHP/miR-140. (c) Relative glycosaminoglycan (GAG) content after 12 weeks. (d) Articular space width in the medial compartment of the mouse knee joints 12 weeks after surgery. (e) OARSI score for each group after 12 weeks. Reproduced from ref. 193 with permission from Springer Nature, copyright 2022.

Similarly, MMP-13-responsive hydrogel microspheres were used to control the release of celecoxib-loaded liposomes in the context of OA.¹⁹⁴ Compared to microspheres immersed in

hyaluronidase only, the drug release efficiency reached 82% on day 5 after immersion in the solution containing MMP13 and hyaluronidase, indicating a significantly accelerated release of



celecoxib in the presence of MMP13 (Fig. 6b). After inducing OA in rats *via* ACL transection and partial medial meniscectomy, intra-articular injection of these microspheres yielded a significant reduction in cartilage degeneration,¹⁹⁴ as shown by a lower OA score, larger joint space width and reduced osteophyte formation.

The rate of degradation also depends on the composition and structure of the biomaterial. For example, the release of curcumin from a gelatin scaffold can be prolonged by adding silk fibers to the scaffold.¹⁹⁵ Another study showed that the degradation rate of a scaffold made of PLGA and PLA nanofibers could be adapted by varying the PLGA/PLA ratio: the higher the PLGA/PLA ratio, the faster the scaffold degraded.¹⁹⁶ Finally, cartilage repair is also correlated with mechanical loading applied to the scaffold. Higher shear stresses resulted in early and fast release of sirolimus, with high cumulative drug release.¹⁹⁷

However, achieving precise control of biomolecule delivery solely by adjusting scaffold biodegradation remains limited. One reason is that, depending on the application, it might be

required that the active molecule be released faster than the scaffold degradation rate, which should be consistent with the rate of neo-tissue formation. In contrast, diffusion out of a highly solvated hydrogel is often very fast, hence retention of the active compounds through weak interactions or reversible covalent attachment to the matrix is needed. Different strategies have been explored to achieve optimal delivery profiles of single or multiple drugs.¹⁹⁸ A comprehensive understanding of the interactions and release mechanisms underlying the drug delivery kinetics is key to providing new insights into cartilage repair.

IV.1.3. Weak interactions. Although steric interactions between scaffolds and biomolecules are ubiquitous, other non-covalent interactions can be exploited to finely tune the spatio-temporal release of biomolecules. Electrostatic and hydrophobic non-covalent interactions are widely involved in the interactions between scaffolds and growth factors (Fig. 7).

Several natural macromolecules—abundant in the connective tissues of vertebrates (collagen, heparin, or hyaluronic




Fig. 6 MMP13-responsive hydrogel microspheres for precise delivery of celecoxib. (a) Schematic representation of the responsive release of celecoxib from hydrogel microspheres induced by MMP13. (b) Drug release profiles of celecoxib in HAase, MMP13 and MMP13/HAase solutions. (c) Measurement of joint space width of the lateral knee joint compartment evaluated from X-rays. (d) Relative osteophyte volume measured by micro-CT. (e) OARS scores determined on histological sections of knee joints. Reproduced from ref. 194 with permission from Elsevier, copyright 2024.






Fig. 7 Schematic representation of weak interactions that can be used to control biomolecule delivery from scaffolds with (left) **spontaneous natural interactions** between unmodified biomolecules and the scaffold, (middle) **modified biomolecules** functionalized to improve their affinity for the scaffold, thereby enabling a more sustained release and (right) **heparin semi-interpenetrated scaffold** where heparin (red) is dispersed into the scaffold, enabling stable and enhanced interactions with biomolecules.

acid) and largely used to elaborate scaffolds for TE—exhibit attractive interactions with diffusing active biomolecules. Collagen is the main component of the cartilage ECM and among the most used material for the construction of scaffolds in TE. Some GFs, including TGF- β 1, bFGF and BMP-2, are demonstrated to naturally possess a strong affinity for collagen and can bind to collagen-based scaffolds *via* ionic interactions. However, the release profiles usually feature an initial burst, which makes this approach unsuitable for controlled release.^{199,200} One possibility to enhance their binding to the scaffold and slow down their release is to engineer recombinant GF by adding a collagen binding domain (CBD) at one terminus.^{201,202} Indeed, recombinant PTHrP expressed as a fusion with a CBD heptapeptide displayed a higher collagen-binding capacity than that of the native PTHrP, with a dissociation constant two times lower.²⁰³ Applied to cartilage TE, this engineered peptide allowed for sustained release from a collagen scaffold and a prolonged effect over several days. Conversely, peptides with a strong affinity for specific regions of GFs can be designed and bound to the scaffolds to control the GF presentation and activity.²⁰⁴ The modification of scaffolds with such peptides resulted in higher retention, less dissemination and better controlled release, thus reducing the amount of GFs required and providing a more cost-effective approach for TE applications.^{205–207} Several TGF β 1-binding peptides, including HSNGLPL, have been used to functionalize biopolymer scaffolds, with *in vitro* and *in vivo* applications.^{208–211} Similarly, the incorporation of heparin into scaffolds is widely used for drug delivery purposes.^{193,196,212–215} Indeed, positively charged amino acids of GFs can interact with GAGs through electrostatic interactions, particularly with the sulphate groups of heparan sulphate proteoglycans (HSPGs), which are widely produced in the ECM of tissues.^{213,216–220} For instance, heparin was trapped as a semi-interpenetrated polymer within a cross-linked network or covalently bound to a polymer backbone by grafting tyramine, methacrylate, thiols or maleimide moieties to the heparin chains.^{221–225} Once trapped in the network of polymers or grafted onto the scaffold, electrostatic interactions established between heparin and GFs such as TGF- β or bFGF slowed down their release. Recently, heparin covalently conju-

gated to a hyaluronan hydrogel was shown to achieve the sustained release of 60% TGF- β 1 after two weeks, whereas in the absence of heparin, 97% of TGF- β 1 was released over the same period.²²⁶ The system demonstrated remarkable efficacy for promoting chondrogenesis, as shown by 19- and 32-fold increases in aggrecan and type 2 collagen expression, respectively, after 21 days of differentiation when heparin was covalently conjugated to a hyaluronan hydrogel (Fig. 8).

Interestingly, sulphated alginate, which is used in cartilage TE for its beneficial effects on chondrocyte proliferation and phenotype maintenance, can also act as a GAG analogue and interact with most GFs, thereby extending their therapeutic effect.^{227–231} This dual property of alginate was used to form a macro-porous alginate scaffold, where uronic acid units were sulphated to mimic heparin, and successfully loaded with TGF- β 1 to enhance MSC chondrogenesis.²³² Finally, electrostatic interactions can also be involved, in particular for gene therapy applications using non-viral vectors for gene transfer.^{1,153,233,234} Naked nucleic acids bear a negative charge, while the vectors obtained by complexation with cationic polymers or lipids exhibit a net positive charge.^{183,235} For example, the incorporation of siRNA into positively charged copolymer micelles significantly slowed down the release from injectable polyurethane; this could be attributed in part to attractive electrostatic interactions between the vector and the scaffold matrix.¹⁸³

Hydrophobic interactions also largely participate in the retention of biomolecules in a scaffold. As an example, gelatin or gelatin–silk fibroin microspheres have been used for the sustained release of curcumin adsorbed into the microspheres for the treatment of OA.¹⁹⁵ The slower release rate with gelatin–silk fibroin microspheres than gelatin microspheres was attributed to hydrophobic interactions between curcumin and the hydrophobic domains of the silk fibroin, along with the lower degradation rate compared to that of pure gelatin microspheres. It is also possible to alter the interactions between proteins and scaffolds to control the biomolecule release kinetics. For example, PLGA microspheres have been used as pharmacologically active microcarriers for the delivery of TGF- β 3 to promote the differentiation of MSCs into chondrocytes.²³⁶ In this study, PLGA microspheres were modified






Fig. 8 Injectable heparin-conjugated scaffold for local delivery of TGF-β1. (A) Schematic of the study design. (B) Cumulative TGF-β1 release from hyaluronan gel (HA-TG), hyaluronan gel + heparin–glutamine (HA-TG/Hep-TG) or hyaluronan gel + heparin (HA-TG/Hep). Gene expression after 21 days of differentiation for (C) aggrecan and (D) collagen type II. Reproduced from ref. 226 with permission from Elsevier, copyright 2019.

with poloxamer P188, resulting in a more hydrophilic scaffold and therefore allowing for greater and sustained release of TGF-β3, reaching 70% on day 30. These PLGA microspheres modified with poloxamer P188, exerted a superior effect on chondrogenic differentiation compared to unmodified PLGA-TGF-β3.

IV.2. Covalent interactions

Covalent binding of biomolecules to scaffolds is commonly used to increase retention rates and significantly reduce the initial burst release often observed with non-covalent methods.²³⁷ Biomolecules can be directly grafted to the materials or attached *via* a linker. The immobilization strategies may involve existing chemical functions present on the scaffolds and biomolecules or require previous activation. Because biomolecules are usually not soluble or will be denatured in organic solvents, their bioconjugation requires the use of aqueous-based chemistry. To address these needs,

various activation strategies are being developed, and the main biocompatible chemical immobilization systems adapted to cartilage TE are presented below (see also Table 4) (Fig. 9).

IV.2.1 Direct grafting. One of the most common methods to conjugate biomolecules is the formation of an amide bond between a carboxyl group of the biological factor and a primary amine on the scaffold matrix, or *vice versa*. The zero-length linker 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide hydrochloride (EDC), a water-soluble carbodiimide, is often used to activate the carboxyl groups.^{206,238} EDC is released after the formation of the amide bond, leaving no additional atom between the biomaterial and the biofactor. EDC has been used to conjugate TGF-β1, TGF-β3, BMP-2 and BMP-4 to a variety of biomaterials.^{239–242} The release of TGF-β3 immobilized on the PLGA–gelatin–chondroitin sulphate–HA hybrid scaffold demonstrated a biphasic pattern characterized by a fast release of 14.5% of the initial loading during the first day followed by a plateau on day 7 to reach 29.5% release after






Fig. 9 Different strategies for chemical modifications of the scaffolds or biomolecules, and covalent grafting to control biomolecule delivery from scaffolds. **Crosslinking** of biomolecules to the scaffold using crosslinking agents such as EDC or Traut's reagent, leading to stable attachment in the scaffold. **Biomolecules modified with photoreactive groups** are immobilized onto the scaffold under UV irradiation, enabling localized and precise functionalization. **Scaffolds modified with photoreactive groups** enable immobilization of free biomolecules upon UV exposure, facilitating controlled biomolecule attachment.

28 days. The release of TGF- β 3 induced the chondrogenic differentiation of MSCs.²⁴⁰ To improve biomolecule immobilization, sulfo-*N*-hydroxysuccinimide (sulfo-NHS) is often combined with EDC to form a more stable amine-reactive sulfo-NHS ester intermediate, with improved reaction efficiency in aqueous media.^{205,237,243} The combination of EDC and NHS activation was used to conjugate KGN on chitosan-based nanoparticles (NPs) and microparticles (MPs), which resulted in higher *in vitro* chondrogenic differentiation of MSCs compared to control with unconjugated KGN.²⁴⁴ The *in vitro* release of KGN was compared between MPs and NPs, with 55% of KGN released from MPs and 35% released from NPs over a 50-day period (Fig. 10). Micropellets of MSCs treated with kartogenin-conjugated MPs or NPs exhibited stronger Safranin-O and Alcian blue staining, indicating enhanced proteoglycan synthesis. *In vivo*, the administration of CHI-KGN NPs or CHI-KGN MPs resulted in a reduction of degenerative changes in rats with induced OA, as reflected by a significant reduction in OARSI scores.

However, immobilization on the scaffold and the various necessary steps required can affect the bioactivity of the drug. Carbodiimide coupling can occur with the amine groups present in the lysine residues or N-terminus of GF, as well as the carboxylic groups present in the aspartate or glutamate residues or C-terminus. This lack of selectivity may result in some bioactive functional groups being involved in grafting bond formation, potentially resulting in a loss of GF bioactivity.²⁰⁴ Similarly, the presence of numerous functional groups leads to the random immobilisation of GF, thereby affecting the accessibility of ligands to the corresponding cell receptors.²⁰⁵

IV.2.2. Click chemistry. Click chemistry represents a quick, selective, and high yielding chemical conjugation method without the need for extensive post-processing to remove by-products.^{245,246} Click reactions offer the advantage of being

nontoxic for cells and can be done in water or in complex biological environments avoiding multiple steps that can affect biomolecule/drug bioactivity.²⁴⁷ Among them, thiol-based click strategies are based on reactions with free thiols that are present in cysteine residues of native GFs. Alternatively, thiols can be introduced chemically to the primary amines of biomolecules, notably proteins, using 2-iminothiolane, also known as Traut's reagent.^{248,249} This chemical modification was applied for instance to the immobilization of TGF- β 1 onto an acrylated poly(glycidol) (PG-Acr) hydrogel. Acrylate groups on PG-Acr played roles in both hydrogel formation and conjugation with the thiolated GF *via* Michael-type addition. Grafting of TGF- β 1 did not compromise hydrogel formation and improved the chondrogenesis of encapsulated MSCs compared to gels with TGF- β 1 simply impregnated without thiolation.²⁵⁰ The GAG/DNA and collagen/DNA ratios were approximately two times higher and the cartilage ECM was thicker when TGF- β 1 was grafted. This clearly demonstrated the superior effect of covalent immobilization of TGF- β 1 onto the hydrogels compared to non-covalent incorporation.

Another major click chemistry reaction that is attracting a great deal of interest in the biomedical field is strain-promoted azide-alkyne cycloaddition (SPAAC). For example, alkyne groups were added to BMP-2 and azides were added to a methoxy polyethylene glycol-polycaprolactone to facilitate attachment and *in fine* improve cell differentiation.²⁵¹ In another example, hydroxyethyl cellulose (HEC) was modified to make it amenable for biorthogonal click chemistry. This largely available modified natural polymer has been considered for cartilage TE but it lacks reactive functional groups. A method based on an initial esterification step with citric acid to introduce carboxylic functions (handles), which are used to introduce either azide or alkyne (DBCO) moieties, was developed. Alkyne- and azide-modified HEC are then mixed and reacted through SPAAC to form a biocompatible and






Fig. 10 Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles. Cumulative release of KGN from (a) kartogenin-conjugated chitosan microparticles (CHI-KGN MPs) and (b) nanoparticles (CHI-KGN NPs). (c) Safranin-O and Alcian-blue staining of cell micropellets cultured with or without kartogenin, CHI-KGN MPs or CHI-KGN NPs after 3 weeks. (d) OARSI scores from histological sections of medial tibial plateaus of rats injected with vehicle, KGN or implanted with the CHI-KGN MPs or CHI-KGN NPs after 14 weeks. Reproduced from ref. 244 with permission from Elsevier, copyright 2014.

biorthogonal HEC scaffold.²⁵² The reactivity introduced into HEC can be exploited to immobilize biomolecules, for instance, N-terminal azide-modified GF. However, poorly controlled covalent modifications can negatively affect the activity of biomolecules. Therefore, the immobilization strategy should be appropriate for the chemistry of biomaterials, the availability of reactive groups in the biomolecule structure and the location of the reactive groups relative to the receptor binding domain.^{253,254}

IV.2.3. Photoimmobilization. Photoimmobilization is another common method to immobilize biofactors on biomaterials. Photoinitiated reactions provide additional control over the location of biomolecule grafting sites within a 3D structure thanks to localized application of UV irradiation. The biomolecule is first functionalized with a photoreactive group such as benzophenone or azidophenyl.^{255,256} Then, the modified biomolecule is bound to the biomaterial upon exposure to light, typically UV.^{205,206,257} A major advantage of photoimmobilization over other immobilization methods lies in its ability to easily generate GF patterns. By using photomasks or laser scanning light sources, GFs can be immobilized in specific

locations within both 2D and 3D matrices; this enables enhanced control over cell behaviour. BMP-2, PDGF and other GFs were photoimmobilized to promote osteogenesis or chondrogenesis.^{113,258–261} As an example, TGF- β 1 was conjugated to acrylated PEG molecules (acryloyl-PEG-NHS) through the reaction of amine groups on GFs with succinimidyl groups on PEG.²⁶² This PEG-TGF- β 1 conjugate was combined with PEG-diacrylate and the mixture was exposed to UV light to initiate the crosslinking reaction and form a hydrogel. Covalently immobilized TGF- β 1 increased ECM production by vascular smooth muscle cells embedded in the PEG hydrogel. The production of collagen was significantly greater when TGF- β 1 was tethered to the hydrogels than when soluble TGF- β 1 was used. Furthermore, the Young's modulus, which reflects the stiffness of the scaffold, was significantly higher when TGF- β 1 was tethered to the scaffolds.

IV.3. Multi-scaffolding system

Hydrogels are efficient biomaterials for TE, as already widely described, but are limited for the long-term delivery of biomolecules mainly due to the lack of strong interactions to



prevent or slow down the release of molecules.^{261,263–265} To overcome this limitation, drug-loaded MPs or NPs can be incorporated into the hydrogels. Such composite systems, owing to the wide range of chemical structures and properties available for the polymers or inorganic materials, are a strong alternative for the localized entrapment of bioactive cargo, and their controlled and sequential release in cartilage TE²⁶⁶ (Fig. 11).

MPs and NPs display high surface area to volume ratios, small dimensions, high drug encapsulation efficiencies and the capacity to quickly respond to surrounding environmental stimuli, such as temperature, pH, magnetic fields or ultrasound.^{267–269} In this field, the PLGA polymer is widely used due to its controllable degradation profile, ease of manufacture and FDA approval for drug delivery in clinical applications.²⁷⁰ Recently, an injectable hydrogel system (Col-Apt@KGN MPs), which is a collagen-based scaffold containing aptamer 19S (Apt19S) and PLGA-based MPs encapsulating KGN, was described to enable the sequential release of Apt19S and KGN²⁷¹ (Fig. 12). Apt19S was rapidly released from the hydrogel within 6 days, while KGN was slowly released for 33 days *via* the degradation of PLGA MPs. Apt19S enabled the recruitment of endogenous MSCs and KGN promoted their chondrogenic differentiation and cartilage-specific ECM secretion, as confirmed by higher production of GAGs in the Col@KGN MP and Col-Apt@KGN MP groups after 14 and 21 days. In a rabbit model of full-thickness cartilage defects, the Col-Apt@KGN MP group demonstrated the most effective repair, with the regenerated tissue showing a smooth surface and uniform integration into the surrounding healthy cartilage and an ICRS score significantly superior to that of the other groups after 14 weeks.

Another composite scaffold, consisting of an injectable chitosan/silk fibroin hydrogel and PLGA MPs loaded respectively with SDF-1 and KGN, was successfully used to achieve the sequential release of these two biomolecules for cartilage TE.²⁷² The authors suggest that the burst release of SDF-1 (*ca.* 40% after 24 h) accounts for the recruitment of endogenous MSCs to the defect area. The slower and sustained release of

KGN promoted the differentiation of MSCs into chondrocytes, hence favouring cartilage repair. This approach gave interesting results *in vivo*, after creating surgical lesions on rabbit knees.

Finally, polyionic complex NPs loaded with TGF- β 2 were encapsulated into an alginate hydrogel impregnated with BMP-7. This resulted in the sequential delivery of biological factors; BMP-7 was released faster than TGF- β 2, with 80% and 30% of the GF, respectively, being released after 21 days of incubation.²⁷³ Since the molecular weight of the polymer that forms the particles could affect the release kinetics of the encapsulated drug, this property was also evaluated to tune the release of different active compounds. *In vitro*, TGF β 3 loaded into low-molecular-weight PLGA (10 kDa)-based MPs exhibited sustained release over 28 days, reaching approximately 96% of the initial dose.²⁷⁴ In contrast, lenvatinib, an anti-angiogenic small molecule, was released at a much slower rate from high-molecular-weight PLGA (100 kDa)-based MPs, with only 40% being released after 56 days. Although TGF β 3 and lenvatinib have distinct chemical natures, their dual release from 10 kDa and 100 kDa PLGA MPs resulted in the significant downregulation of osteogenesis-related genes (BMP2, RUNX2, OPN, OCN, ALP) being observed after 56 days.

Processing and 3D structures, as described in section II.3, offer versatile strategies for manipulating drug loading and release profiles from scaffolds.^{139,275} Layer-by-layer assembly is commonly used to construct porous scaffolds with good performance in avoiding GF loss of function, while achieving a high sequestration rate under mild aqueous conditions and controlled delivery. A method for the 3D printing of hydrogels with core-shell capsules sensitive to external stimuli was developed for the on-demand release of biomolecules.²⁷⁶ The capsules consisted of an aqueous core, which could be formulated to maintain the activity of payload biomolecules—here, the horse peroxidase (HRP) protein was used as a proof-of-concept—and a PLGA shell that sterically held the molecules inside the capsules. The shell is loaded with plasmonic gold nanorods (AuNR) that selectively disrupt the capsules when irradiated with a laser at a specific wavelength, therefore triggering




Fig. 11 Schematic representation of composite systems used to control biomolecule delivery from scaffolds. Nanoparticles (NPs) or microparticles (MPs) embedded within the scaffold matrix as localized biomolecule reservoirs. Layer-by-layer (LBL) assembly, creating stratified layers of varying densities for the precise spatial distribution and controlled release of biomolecules.






Fig. 12 Spatiotemporal sequential releasing hydrogel for cartilage regeneration. (A) Fabrication of a collagen hydrogel incorporating I-Apt19S and KGN-loaded PLGA microspheres (Col-Apt@KGN MPs). (B) Cumulative drug release over 33 days *in vitro*. (C) Quantitative determination of the sGAG/DNA ratio after 14 days and 21 days. (D) ICRS macroscopic score evaluating cartilage repair. Reproduced from ref. 271 with permission from RSC, copyright 2008.

the release of HRP with high spatiotemporal control.²⁷⁶ Similarly, TGF- β 1-embedding core-shell nanospheres were fabricated *via* co-axial electrospaying of the GF along with PLGA and then mixed to form a bioink composed of 10% gelatin methacrylate (GelMA), 5% polyethylene glycol diacrylate (PEGDA) and a biocompatible photoinitiator.²⁷⁷ The MSC-laden constructs were 3D bioprinted by stereolithography and the sustained release of TGF- β 1 for up to 21 days significantly improved the chondrogenic differentiation of encapsulated MSCs.

V. Challenges and future perspectives

Despite considerable advances being made in optimising scaffold design and association with bioactive molecules, clinical translation has achieved only limited success in the treatment of articular cartilage defects. While pre-clinical experiments in small and large animal models have yielded promising results, further investigation is necessary to assess the clinical safety, reliability, and efficacy of the TE strategy. With regard to the controlled release of drugs over space and time, the majority of research revolves around conditions simulated *in vitro*. However, there is a lack of clear evidence regarding the actual dosage and kinetics of growth factor release *in vivo*. It is necessary to create reliable assessment tools that can noninvasively track growth factor delivery after implantation. Real-time

monitoring in living organisms represents one of the main challenges that requires urgent consideration, in particular for cartilage TE.

A further issue that requires attention is the occurrence of hypertrophic or fibrotic neotissue over time following scaffold implantation in cartilage repair strategies. It is of paramount importance to prevent hypertrophy or fibrosis to enable appropriate integration between the implant and surrounding endogenous tissues. To address this challenge, the incorporation of anti-hypertrophic or anti-fibrotic cues may enhance the stability and longevity of engineered cartilage, thereby advancing the field closer to developing functional cartilage repair therapies. It is therefore crucial to gain a deeper understanding of the precise timing and dosage for their application and to control their release from scaffolds. Concurrently, cell source modulation, genetic engineering and optimisation of culture conditions will be pivotal factors in the translation of TE approaches for clinical success.

The microenvironment-responsive release approach is emerging as a promising solution for controlling the timing of molecule release. The use of cleavable linkers, such as those sensitive to pH or proteases, represents a significant opportunity to selectively release active molecules in response to changes in the nearby tissue environment, thereby controlling the temporal and spatial availability of specific factors for optimized tissue regeneration. Future strategies will undoubtedly benefit from evolving advances in monitoring, fabrication techniques and novel strategic pairings of biomolecules.



VI. Conclusion

Cartilage TE seeks to generate neo-tissue that mimics the physiological function of native cartilage, offering a viable solution for cartilage repair. However, existing strategies often result in the deposition of an ECM with suboptimal biomechanical properties that degrade over time, poor integration into the host tissue or tissue fibrosis. To enhance cartilage regeneration using scaffolds containing MSCs or chondrocytes, various biomolecules have been incorporated into different types of biomaterials in order to boost their biological activity and reduce the need for repeated injections. These biofactors play crucial roles in differentiation processes or cartilage homeostasis and typically require sustained release due to their rapid clearance *in vivo*. Moreover, the kinetics of their release must be tailored to the specific biofactor. Recent advances have successfully employed scaffolds as biomolecule reservoirs, ensuring prolonged release of active molecules over weeks or even months, with promising outcomes for cartilage engineering. Innovations in biomaterials chemistry have further improved the control and retention of biomolecules within scaffolds, preserving their bioactivity. However, the majority of controlled release research is conducted *in vitro*, under simulated conditions, and the absence of real-time monitoring in living organisms remains a major limitation, hindering further progress in the field. It is clear that future strategies will greatly benefit from the integration of advanced monitoring technologies, innovative fabrication techniques, and the development of novel agent combinations. Additionally, cleavable linkers, responsive to pH or proteases, offer a promising approach for the selective release of active molecules in response to dynamic changes in the local tissue environment, representing a critical avenue for future research and application in cartilage TE.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Conflicts of interest

There are no conflicts to declare.

References

- 1 A. Saraf and A. G. Mikos, Gene delivery strategies for cartilage tissue engineering, *Adv. Drug Delivery Rev.*, 2006, **58**(4), 592–603.
- 2 T. A. Ahmed and M. T. Hincke, Strategies for articular cartilage lesion repair and functional restoration, *Tissue Eng., Part B*, 2010, **16**(3), 305–329.

- 3 J. E. Browne and T. P. Branch, Surgical alternatives for treatment of articular cartilage lesions, *J. Am. Acad. Orthop. Surg.*, 2000, **8**(3), 180–189.
- 4 E. B. Hunziker, Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects, *Osteoarthritis Cartilage*, 2002, **10**(6), 432–463.
- 5 A. R. Armiento, M. J. Stoddart, M. Alini and D. Eglin, Biomaterials for articular cartilage tissue engineering: Learning from biology, *Acta Biomater.*, 2018, **65**, 1–20.
- 6 J. B. Costa, H. Pereira, J. Espregueira-Mendes, G. Khang, J. M. Oliveira and R. L. Reis, Tissue engineering in orthopaedic sports medicine: current concepts, *J. ISAKOS*, 2017, **2**(2), 60–66.
- 7 J. A. Buckwalter, H. J. Mankin and A. J. Grodzinsky, Articular cartilage and osteoarthritis, *Instr. Course Lect.*, 2005, **54**, 465–480.
- 8 J. A. Buckwalter, S. L. Woo, V. M. Goldberg, E. C. Hadley, F. Booth, T. R. Oegema, *et al.*, Soft-tissue aging and musculoskeletal function, *J. Bone Joint Surg. Am.*, 1993, **75**(10), 1533–1548.
- 9 M. W. Kessler, G. Ackerman, J. S. Dines and D. Grande, Emerging technologies and fourth generation issues in cartilage repair, *Sports Med. Arthrosc. Rev.*, 2008, **16**(4), 246–254.
- 10 E. Perrier-Groult, M. Padeloup, M. Malbouyres, P. Galéra and F. Mallein-Gerin, Control of collagen production in mouse chondrocytes by using a combination of bone morphogenetic protein-2 and small interfering RNA targeting Col1a1 for hydrogel-based tissue-engineered cartilage, *Tissue Eng., Part C*, 2013, **19**(8), 652–664.
- 11 A. J. Rosenbaum, D. A. Grande and J. S. Dines, The use of mesenchymal stem cells in tissue engineering: A global assessment, *Organogenesis*, 2008, **4**(1), 23–27.
- 12 H. Nejadnik, J. H. Hui, E. P. F. Choong, B. C. Tai and E. H. Lee, Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study, *Am. J. Sports Med.*, 2010, **38**(6), 1110–1116.
- 13 I. Uzieliene, E. Bagdonas, K. Hoshi, T. Sakamoto, A. Hikita, Z. Tachtamisevaite, *et al.*, Different phenotypes and chondrogenic responses of human menstrual blood and bone marrow mesenchymal stem cells to activin A and TGF-beta3, *Stem Cell Res. Ther.*, 2021, **12**(1), 251.
- 14 M. Maumus, J. A. Peyrafitte, R. D'Angelo, C. Fournier-Wirth, A. Bouloumie, L. Casteilla, *et al.*, Native human adipose stromal cells: localization, morphology and phenotype, *Int. J. Obes.*, 2011, **35**(9), 1141–1153.
- 15 T. M. Liu, M. Martina, D. W. Hutmacher, J. H. Hui, E. H. Lee and B. Lim, Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages, *Stem Cells*, 2007, **25**(3), 750–760.
- 16 T. Hennig, H. Lorenz, A. Thiel, K. Goetzke, A. Dickhut, F. Geiger, *et al.*, Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an



- altered TGFbeta receptor and BMP profile and is overcome by BMP-6, *J. Cell Physiol.*, 2007, **211**(3), 682–691.
- 17 Q. L. Loh and C. Choong, Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size, *Tissue Eng., Part B*, 2013, **19**(6), 485–502.
 - 18 I. Bruzauskaitė, D. Bironaitė, E. Bagdonas and E. Bernotienė, Scaffolds and cells for tissue regeneration: different scaffold pore sizes-different cell effects, *Cytotechnology*, 2016, **68**(3), 355–369.
 - 19 T. Takahashi, T. Ogasawara, Y. Asawa, Y. Mori, E. Uchinuma, T. Takato, *et al.*, Three-dimensional micro-environments retain chondrocyte phenotypes during proliferation culture, *Tissue Eng.*, 2007, **13**(7), 1583–1592.
 - 20 X. Zhang, Y. Wu, Z. Pan, H. Sun, J. Wang, D. Yu, *et al.*, The effects of lactate and acid on articular chondrocytes function: Implications for polymeric cartilage scaffold design, *Acta Biomater.*, 2016, **42**, 329–340.
 - 21 Y. G. Koh, J. A. Lee, Y. S. Kim, H. Y. Lee, H. J. Kim and K. T. Kang, Optimal mechanical properties of a scaffold for cartilage regeneration using finite element analysis, *J. Tissue Eng.*, 2019, **10**, 2041731419832133.
 - 22 F. J. O'Brien, Biomaterials & scaffolds for tissue engineering, *Mater. Today*, 2011, **14**(3), 88–95.
 - 23 F. T. Moutos and F. Guilak, Composite scaffolds for cartilage tissue engineering, *Biorheology*, 2008, **45**(3–4), 501–512.
 - 24 M. Wasyleczko, W. Sikorska and A. Chwojnowski, Review of Synthetic and Hybrid Scaffolds in Cartilage Tissue Engineering, *Membranes*, 2020, **10**(11), 348.
 - 25 M. Krishani, W. Y. Shin, H. Suhaimi and N. S. Sambudi, Development of Scaffolds from Bio-Based Natural Materials for Tissue Regeneration Applications: A Review, *Gels*, 2023, **9**(2), 100.
 - 26 D. C. Crawford, C. M. Heveran, W. D. Cannon, L. F. Foo and H. G. Potter, An autologous cartilage tissue implant NeoCart for treatment of grade III chondral injury to the distal femur: prospective clinical safety trial at 2 years, *Am. J. Sports Med.*, 2009, **37**(7), 1334–1343.
 - 27 V. Irawan, T. C. Sung, A. Higuchi and T. Ikoma, Collagen Scaffolds in Cartilage Tissue Engineering and Relevant Approaches for Future Development, *Tissue Eng. Regener. Med.*, 2018, **15**(6), 673–697.
 - 28 I. Lukin, I. Erezuma, L. Maeso, J. Zarate, M. F. Desimone, T. H. Al-Tel, *et al.*, Progress in Gelatin as Biomaterial for Tissue Engineering, *Pharmaceutics*, 2022, **14**(6), 1177.
 - 29 H. W. Liu, W. T. Su, C. Y. Liu and C. C. Huang, Highly Organized Porous Gelatin-Based Scaffold by Microfluidic 3D-Foaming Technology and Dynamic Culture for Cartilage Tissue Engineering, *Int. J. Mol. Sci.*, 2022, **23**(15), 8449.
 - 30 E. Arslan, M. Sardan Ekiz, C. Eren Cimenci, N. Can, M. H. Gemci, H. Ozkan, *et al.*, Protective therapeutic effects of peptide nanofiber and hyaluronic acid hybrid membrane in in vivo osteoarthritis model, *Acta Biomater.*, 2018, **73**, 263–274.
 - 31 M. Wang, Z. Deng, Y. Guo and P. Xu, Designing functional hyaluronic acid-based hydrogels for cartilage tissue engineering, *Mater. Today Bio*, 2022, **17**, 100495.
 - 32 C. E. Garcia Garcia, B. Lardy, F. Bossard, F. A. Soltero Martinez and M. Rinaudo, Chitosan based biomaterials for cartilage tissue engineering: Chondrocyte adhesion and proliferation, *Food Hydrocolloids Health*, 2021, **1**, 100018.
 - 33 A. Sadeghianmaryan, S. Naghieh, H. Alizadeh Sardroud, Z. Yazdanpanah, Y. Afzal Soltani, J. Sernaglia, *et al.*, Extrusion-based printing of chitosan scaffolds and their in vitro characterization for cartilage tissue engineering, *Int. J. Biol. Macromol.*, 2020, **164**, 3179–3192.
 - 34 S. Varghese, N. S. Hwang, A. C. Canver, P. Theprungsirikul, D. W. Lin and J. Elisseeff, Chondroitin sulfate based niches for chondrogenic differentiation of mesenchymal stem cells, *Matrix Biol.*, 2008, **27**(1), 12–21.
 - 35 Y. Chen, W. Xu, M. Shafiq, D. Song, X. Xie, Z. Yuan, *et al.*, Chondroitin sulfate cross-linked three-dimensional tailored electrospun scaffolds for cartilage regeneration, *Biomater. Adv.*, 2022, **134**, 112643.
 - 36 A. B. Bonhome-Espinosa, F. Campos, D. Durand-Herrera, J. D. Sánchez-López, S. Schaub, J. D. G. Durán, *et al.*, In vitro characterization of a novel magnetic fibrin-agarose hydrogel for cartilage tissue engineering, *J. Mech. Behav. Biomed. Mater.*, 2020, **104**, 103619.
 - 37 M. Farokhi, F. Jonidi Shariatzadeh, A. Solouk and H. Mirzadeh, Alginate Based Scaffolds for Cartilage Tissue Engineering: A Review, *Int. J. Polym. Mater. Polym. Biomater.*, 2020, **69**(4), 230–247.
 - 38 C. C. Huang, Characteristics and Preparation of Designed Alginate-Based Composite Scaffold Membranes with Decellularized Fibrous Micro-Scaffold Structures from Porcine Skin, *Polymers*, 2021, **13**(20), 3464.
 - 39 U. Urtaza, O. Guaresti, I. Gorroñogoitia, A. Zubiarrain-Laserna, E. Muiños-López, F. Granero-Moltó, *et al.*, 3D printed bioresorbable scaffolds for articular cartilage tissue engineering: a comparative study between neat polycaprolactone (PCL) and poly(lactide-b-ethylene glycol) (PLA-PEG) block copolymer, *Biomed. Mater.*, 2022, **17**(4), 045028.
 - 40 D. H. Rosenzweig, E. Carelli, T. Steffen, P. Jarzem and L. Haglund, 3D-Printed ABS and PLA Scaffolds for Cartilage and Nucleus Pulposus Tissue Regeneration, *Int. J. Mol. Sci.*, 2015, **16**(7), 15118–15135.
 - 41 M. S. Singhvi, S. S. Zinjarde and D. V. Gokhale, Polylactic acid: synthesis and biomedical applications, *J. Appl. Microbiol.*, 2019, **127**(6), 1612–1626.
 - 42 D. da Silva, M. Kaduri, M. Poley, O. Adir, N. Krinsky, J. Shainsky-Roitman, *et al.*, Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems, *Chem. Eng. J.*, 1996. 2018, **340**, 9–14.
 - 43 K. Budak, O. Sogut and U. Aydemir Sezer, A review on synthesis and biomedical applications of polyglycolic acid, *J. Polym. Res.*, 2020, **27**(8), 208.
 - 44 M. Morille, K. Toupet, C. N. Montero-Menei, C. Jorgensen and D. Noël, PLGA-based microcarriers induce mesenchy-



- mal stem cell chondrogenesis and stimulate cartilage repair in osteoarthritis, *Biomaterials*, 2016, **88**, 60–69.
- 45 N. R. Eviana Putri, X. Wang, Y. Chen, X. Li, N. Kawazoe and G. Chen, Preparation of PLGA-collagen hybrid scaffolds with controlled pore structures for cartilage tissue engineering, *Prog. Nat. Sci.: Mater. Int.*, 2020, **30**(5), 642–650.
- 46 J. K. Venkatesan, W. Meng, A. Rey-Rico, G. Schmitt, S. Speicher-Mentges, C. Falentin-Daudré, *et al.*, Enhanced Chondrogenic Differentiation Activities in Human Bone Marrow Aspirates via sox9 Overexpression Mediated by pNaSS-Grafted PCL Film-Guided rAAV Gene Transfer, *Pharmaceutics*, 2020, **12**(3), 280.
- 47 K. Theodoridis, E. Aggelidou, M. Manthou, E. Demiri, A. Bakopoulou and A. Kritis, Assessment of cartilage regeneration on 3D collagen-polycaprolactone scaffolds: Evaluation of growth media in static and in perfusion bioreactor dynamic culture, *Colloids Surf., B*, 2019, **183**, 110403.
- 48 K. Riewruja, A. M. Aguglia, S. Hines, M. J. Makarczyk, S. Honsawek and H. Lin, PEG Reinforced Scaffold Promotes Uniform Distribution of Human MSC-Created Cartilage Matrix, *Gels*, 2022, **8**(12), 794.
- 49 A. Cheng, Z. Schwartz, A. Kahn, X. Li, Z. Shao, M. Sun, *et al.*, Advances in Porous Scaffold Design for Bone and Cartilage Tissue Engineering and Regeneration, *Tissue Eng., Part B*, 2019, **25**(1), 14–29.
- 50 M. Setayeshmehr, E. Esfandiari, M. Rafieinia, B. Hashemibeni, A. Taheri-Kafrani, A. Samadikuchaksaraei, *et al.*, Hybrid and Composite Scaffolds Based on Extracellular Matrices for Cartilage Tissue Engineering, *Tissue Eng., Part B*, 2019, **25**(3), 202–224.
- 51 Z. Ge, C. Li, B. C. Heng, G. Cao and Z. Yang, Functional biomaterials for cartilage regeneration, *J. Biomed. Mater. Res., Part A*, 2012, **100**(9), 2526–2536.
- 52 J. K. Leach and J. Whitehead, Materials-Directed Differentiation of Mesenchymal Stem Cells for Tissue Engineering and Regeneration, *ACS Biomater. Sci. Eng.*, 2018, **4**(4), 1115–1127.
- 53 B. D. Ulery, L. S. Nair and C. T. Laurencin, Biomedical applications of biodegradable polymers, *J. Polym. Sci., Part B: Polym. Phys.*, 2011, **49**(12), 832–864.
- 54 S. V. Vlierbergh, E. Schacht and P. Dubruel, Reversible gelatin-based hydrogels: Finetuning of material properties, *Eur. Polym. J.*, 2011, **47**(5), 1039–1047.
- 55 K. Kabiri, H. Omidian, S. A. Hashemi and M. J. Zohuriaan-Mehr, Synthesis of fast-swelling superabsorbent hydrogels: effect of crosslinker type and concentration on porosity and absorption rate, *Eur. Polym. J.*, 2003, **39**(7), 1341–1348.
- 56 A. C. Daly, L. Riley, T. Segura and J. A. Burdick, Hydrogel microparticles for biomedical applications, *Nat. Rev. Mater.*, 2020, **5**(1), 20–43.
- 57 A. K. Badekila, S. Kini and A. K. Jaiswal, Fabrication techniques of biomimetic scaffolds in three-dimensional cell culture: A review, *J. Cell Physiol.*, 2021, **236**(2), 741–762.
- 58 A. Kumar and A. Jacob, Techniques in scaffold fabrication process for tissue engineering applications: A review, *J. Appl. Biol. Biotechnol.*, 2022, **10**(3), 163–176.
- 59 E. Aram and S. Mehdipour-Ataei, A review on the micro- and nanoporous polymeric foams: Preparation and properties, *Int. J. Polym. Mater. Polym. Biomater.*, 2016, **65**(7), 358–375.
- 60 G. Conoscenti, T. Schneider, K. Stoelzel, F. Carfi Pavia, V. Brucato, C. Goegele, *et al.*, PLLA scaffolds produced by thermally induced phase separation (TIPS) allow human chondrocyte growth and extracellular matrix formation dependent on pore size, *Mater. Sci. Eng., C*, 2017, **80**, 449–459.
- 61 T. Lu, Y. Li and T. Chen, Techniques for fabrication and construction of three-dimensional scaffolds for tissue engineering, *Int. J. Nanomed.*, 2013, **8**, 337–350.
- 62 D. Li and Y. Xia, Electrospinning of Nanofibers: Reinventing the Wheel?, *Adv. Mater.*, 2004, **16**(14), 1151–1170.
- 63 K. Ye, H. Kuang, Z. You, Y. Morsi and X. Mo, Electrospun Nanofibers for Tissue Engineering with Drug Loading and Release, *Pharmaceutics*, 2019, **11**(4), 182.
- 64 E. Amler, E. Filová, M. Buzgo, E. Prosecká, M. Rampichová, A. Nečas, *et al.*, Functionalized nanofibers as drug-delivery systems for osteochondral regeneration, *Nanomedicine*, 2014, **9**, 1083–1094.
- 65 M. Rafiei, E. Jooybar, M. J. Abdekhodaie and M. Alvi, Construction of 3D fibrous PCL scaffolds by coaxial electrospinning for protein delivery, *Mater. Sci. Eng., C*, 2020, **113**, 110913.
- 66 F. Sharifi, S. Irani, G. Azadegan, M. Pezeshki-Modaress, M. Zandi and M. Saeed, Co-electrospun gelatin-chondroitin sulfate/polycaprolactone nanofibrous scaffolds for cartilage tissue engineering, *Bioact. Carbohydr. Diet. Fibre*, 2020, **22**, 100215.
- 67 A. Zaszczynska, M. Moczulska-Heljak, A. Gradys and P. Sajkiewicz, Advances in 3D Printing for Tissue Engineering, *Materials*, 2021, **14**(12), 3149.
- 68 G. Gao and X. Cui, Three-dimensional bioprinting in tissue engineering and regenerative medicine, *Biotechnol. Lett.*, 2016, **38**(2), 203–211.
- 69 S. M. Bittner, J. L. Guo and A. G. Mikos, Spatiotemporal Control of Growth Factors in Three-Dimensional Printed Scaffolds, *Bioprinting*, 2018, **12**, e00032.
- 70 Y. Wang, C. Ling, J. Chen, H. Liu, Q. Mo, W. Zhang, *et al.*, 3D-printed composite scaffold with gradient structure and programmed biomolecule delivery to guide stem cell behavior for osteochondral regeneration, *Biomater. Adv.*, 2022, **140**, 213067.
- 71 B. G. Pavan Kalyan and L. Kumar, 3D Printing: Applications in Tissue Engineering, Medical Devices, and Drug Delivery, *AAPS PharmSciTech*, 2022, **23**(4), 92.
- 72 M. Dufaud, L. Solé, M. Maumus, M. Simon, E. Perrier-Groult, G. Subra, *et al.*, 3D bioprinting of articular cartilage: Recent advances and perspectives, *Bioprinting*, 2022, **28**, e00253.




- 73 K. Johnson, S. Zhu, M. S. Tremblay, J. N. Payette, J. Wang, L. C. Bouchez, *et al.*, A stem cell-based approach to cartilage repair, *Science*, 2012, **336**(6082), 717–721.
- 74 G. Cai, W. Liu, Y. He, J. Huang, L. Duan, J. Xiong, *et al.*, Recent advances in kartogenin for cartilage regeneration, *J. Drug Targeting*, 2019, **27**(1), 28–32.
- 75 M. Wu, C. Li, G. Zhu, Y. Wang, J. Jules, Y. Lu, *et al.*, Deletion of Core-binding factor β (Cbfb) in mesenchymal progenitor cells provides new insights into Cbfb/Runx complex function in cartilage and bone development, *Bone*, 2014, **65**, 49–59.
- 76 X. Li, J. Ding, Z. Zhang, M. Yang, J. Yu, J. Wang, *et al.*, Kartogenin-Incorporated Thermogel Supports Stem Cells for Significant Cartilage Regeneration, *ACS Appl. Mater. Interfaces*, 2016, **8**(8), 5148–5159.
- 77 H. Yin, J. Wang, Z. Gu, W. Feng, M. Gao, Y. Wu, *et al.*, Evaluation of the potential of kartogenin encapsulated poly(L-lactic acid-co-caprolactone)/collagen nanofibers for tracheal cartilage regeneration, *J. Biomater. Appl.*, 2017, **32**(3), 331–341.
- 78 D. Shi, X. Xu, Y. Ye, K. Song, Y. Cheng, J. Di, *et al.*, Photo-Cross-Linked Scaffold with Kartogenin-Encapsulated Nanoparticles for Cartilage Regeneration, *ACS Nano*, 2016, **10**(1), 1292–1299.
- 79 W. Zhang, G. Tang, B. Zhu, M. Yan, F. Yu, X. Wang, *et al.*, Fabrication of an injectable hydrogel scaffold embedding kartogenin-encapsulated PLGA microsphere with long-term drug release to promote chondrogenesis, *React. Funct. Polym.*, 2024, **196**, 105821.
- 80 Y. Zhao, X. Zhao, R. Zhang, Y. Huang, Y. Li, M. Shan, *et al.*, Cartilage Extracellular Matrix Scaffold With Kartogenin-Encapsulated PLGA Microspheres for Cartilage Regeneration, *Front. Bioeng. Biotechnol.*, 2020, **8**, 600103.
- 81 S. Shishodia, T. Singh and M. M. Chaturvedi, Modulation of transcription factors by curcumin, *Adv. Exp. Med. Biol.*, 2007, **595**, 127–148.
- 82 B. Chandran and A. Goel, A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis, *Phytother. Res.*, 2012, **26**(11), 1719–1725.
- 83 T. Masuda, K. Hidaka, A. Shinohara, T. Maekawa, Y. Takeda and H. Yamaguchi, Chemical studies on anti-oxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin, *J. Agric. Food Chem.*, 1999, **47**(1), 71–77.
- 84 D. K. Kim, J. I. Kim, B. R. Sim and G. Khang, Bioengineered porous composite curcumin/silk scaffolds for cartilage regeneration, *Mater. Sci. Eng., C*, 2017, **78**, 571–578.
- 85 C. Buhmann, A. Mobasheri, U. Matis and M. Shakibaei, Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment, *Arthritis Res. Ther.*, 2010, **12**(4), 127.
- 86 A. M. Gorabi, N. Kiaie, S. Hajighasemi, T. Jamialahmadi, M. Majeed and A. Sahebkar, The Effect of Curcumin on the Differentiation of Mesenchymal Stem Cells into Mesodermal Lineage, *Molecules*, 2019, **24**(22), 4029.
- 87 J. Salazar, L. Bello, M. Chávez, R. Añez, J. Rojas and V. Bermúdez, Glucosamine for Osteoarthritis: Biological Effects, Clinical Efficacy, and Safety on Glucose Metabolism, *Arthritis*, 2014, **2014**, e432463.
- 88 I. Nagaoka, M. Igarashi and K. Sakamoto, Biological Activities of Glucosamine and Its Related Substances, in *Advances in Food and Nutrition Research [Internet]*, ed. S. K. Kim, Academic Press, 2012, ch. 22, pp. 337–352. (Marine Medicinal Foods; vol. 65). Available from: <https://www.sciencedirect.com/science/article/pii/B9780124160033000226> [cited 2024 May 30].
- 89 C. Li, Q. Li, Q. Mei and T. Lu, Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii, *Life Sci.*, 2015, **126**, 57–68.
- 90 D. Li, T. Yuan, X. Zhang, Y. Xiao, R. Wang, Y. Fan, *et al.*, Icariin: a potential promoting compound for cartilage tissue engineering, *Osteoarthritis Cartilage*, 2012, **20**(12), 1647–1656.
- 91 Z. C. Wang, H. J. Sun, K. H. Li, C. Fu and M. Z. Liu, Icariin promotes directed chondrogenic differentiation of bone marrow mesenchymal stem cells but not hypertrophy in vitro, *Exp. Ther. Med.*, 2014, **8**(5), 1528–1534.
- 92 L. Zhang, X. Zhang, K. F. Li, D. X. Li, Y. M. Xiao, Y. J. Fan, *et al.*, Icariin promotes extracellular matrix synthesis and gene expression of chondrocytes in vitro, *Phytother. Res.*, 2012, **26**(9), 1385–1392.
- 93 Y. Luo, Y. Zhang and Y. Huang, Icariin Reduces Cartilage Degeneration in a Mouse Model of Osteoarthritis and is Associated with the Changes in Expression of Indian Hedgehog and Parathyroid Hormone-Related Protein, *Med. Sci. Monit.*, 2018, **24**, 6695–6706.
- 94 C. C. Wei, D. Q. Ping, F. T. You, C. Y. Qiang and C. Tao, Icariin Prevents Cartilage and Bone Degradation in Experimental Models of Arthritis, *Mediators Inflammation*, 2016, **2016**, 9529630.
- 95 M. Pei, F. He, L. Wei and A. Rawson, Melatonin enhances cartilage matrix synthesis by porcine articular chondrocytes, *J. Pineal Res.*, 2009, **46**(2), 181–187.
- 96 W. Gao, M. Lin, A. Liang, L. Zhang, C. Chen, G. Liang, *et al.*, Melatonin enhances chondrogenic differentiation of human mesenchymal stem cells, *J. Pineal Res.*, 2014, **56**(1), 62–70.
- 97 T. Li, B. Liu, K. Chen, Y. Lou, Y. Jiang and D. Zhang, Small molecule compounds promote the proliferation of chondrocytes and chondrogenic differentiation of stem cells in cartilage tissue engineering, *Biomed. Pharmacother.*, 2020, **131**, 110652.
- 98 Y. Zhang, T. Liu, H. Yang, F. He and X. Zhu, Melatonin: A novel candidate for the treatment of osteoarthritis, *Ageing Res. Rev.*, 2022, **78**, 101635.
- 99 Z. Wu, X. Qiu, B. Gao, C. Lian, Y. Peng, A. Liang, *et al.*, Melatonin-mediated miR-526b-3p and miR-590-5p upregulation promotes chondrogenic differentiation of human



- mesenchymal stem cells, *J. Pineal Res.*, 2018, **65**(1), e12483.
- 100 Z. Zhang, J. Lin, N. Tian, Y. Wu, Y. Zhou, C. Wang, *et al.*, Melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway, *J. Cell. Mol. Med.*, 2019, **23**(1), 177–193.
- 101 A. J. Theruvath, E. E. Mahmoud, W. Wu, H. Nejadnik, L. Kiru, T. Liang, *et al.*, Ascorbic Acid and Iron Supplement Treatment Improves Stem Cell-Mediated Cartilage Regeneration in a Minipig Model, *Am. J. Sports Med.*, 2021, **49**(7), 1861–1870.
- 102 S. Murad, D. Grove, K. A. Lindberg, G. Reynolds, A. Sivarajah and S. R. Pinnell, Regulation of collagen synthesis by ascorbic acid, *Proc. Natl. Acad. Sci. U. S. A.*, 1981, **78**(5), 2879–2882.
- 103 Y. Sato, H. Mera, D. Takahashi, T. Majima, N. Iwasaki, S. Wakitani, *et al.*, Synergistic effect of ascorbic acid and collagen addition on the increase in type 2 collagen accumulation in cartilage-like MSC sheet, *Cytotechnology*, 2017, **69**(3), 405–416.
- 104 T. F. Li, R. J. O'Keefe and D. Chen, *TGF-beta signaling in chondrocytes*, *Frontiers in bioscience : a journal and virtual library* 10, 2005, pp. 681–688.
- 105 W. Wang, D. Rigueur and K. M. Lyons, TGFbeta signaling in cartilage development and maintenance, *Birth Defects Res., Part C*, 2014, **102**(1), 37–51.
- 106 P. M. Kraan, E. N. B. Davidson, A. Blom and W. B. Berg, TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads, *Osteoarthritis Cartilage*, 2009, **17**(12), 1539–1545.
- 107 A. Weiss and L. Attisano, The TGFbeta superfamily signaling pathway, Wiley interdisciplinary reviews, *Dev. Biol.*, 2013, **2**(1), 47–63.
- 108 A. P. Hinck, Structural studies of the TGF-betas and their receptors - insights into evolution of the TGF-beta superfamily, *FEBS Lett.*, 2012, **586**(14), 1860–1870.
- 109 D. Horbelt, A. Denkis and P. Knaus, A portrait of Transforming Growth Factor beta superfamily signalling: Background matters, *Int. J. Biochem. Cell Biol.*, 2012, **44**(3), 469–474.
- 110 M. B. Mueller, M. Fischer, J. Zellner, A. Berner, T. Dienstknecht, L. Prantl, *et al.*, Hypertrophy in Mesenchymal Stem Cell Chondrogenesis: Effect of TGF- β Isoforms and Chondrogenic Conditioning, *Cells Tissues Organs*, 2010, **192**(3), 158–166.
- 111 A. T. Mehlhorn, H. Schmal, S. Kaiser, G. Lepski, G. Finkenzeller, G. B. Stark, *et al.*, Mesenchymal Stem Cells Maintain TGF- β -Mediated Chondrogenic Phenotype in Alginate Bead Culture, *Tissue Eng.*, 2006, **12**(6), 1393–1403.
- 112 X. Yang, S. Tian, L. Fan, R. Niu, M. Yan, S. Chen, *et al.*, Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells, *Cancer Cell Int.*, 2022, **22**(1), 169.
- 113 Z. H. Deng, Y. S. Li, X. Gao, G. H. Lei and J. Huard, Bone morphogenetic proteins for articular cartilage regeneration, *Osteoarthritis Cartilage*, 2018, **26**(9), 1153–1161.
- 114 A. F. Steinert, B. Proffen, M. Kunz, C. Hendrich, S. C. Ghivizzani, U. Noth, *et al.*, Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer, *Arthritis Res. Ther.*, 2009, **11**(5), 148.
- 115 A. Steinert, M. Weber, A. Dimmler, C. Julius, N. Schütze, U. Nöth, *et al.*, Chondrogenic differentiation of mesenchymal progenitor cells encapsulated in ultrahigh-viscosity alginate, *J. Orthop. Res.*, 2003, **21**(6), 1090–1097.
- 116 N. D. Miljkovic, G. M. Cooper and K. G. Marra, Chondrogenesis, bone morphogenetic protein-4 and mesenchymal stem cells, *Osteoarthritis Cartilage*, 2008, **16**(10), 1121–1130.
- 117 Y. Lópiz-Morales, A. Abarrategi, V. Ramos, C. Moreno-Vicente, L. López-Durán, J. L. López-Lacomba, *et al.*, In vivo comparison of the effects of rhBMP-2 and rhBMP-4 in osteochondral tissue regeneration, *Eur. Cells Mater.*, 2010, **20**, 367–378.
- 118 P. H. Liebesny, K. Mroszczyk, H. Zlotnick, H. H. Hung, E. Frank, B. Kurz, *et al.*, Enzyme Pretreatment plus Locally Delivered HB-IGF-1 Stimulate Integrative Cartilage Repair In Vitro, *Tissue engineering, Part A*, 2019, **25**(17–18), 1191–1201.
- 119 L. Chen, J. Liu, M. Guan, T. Zhou, X. Duan and Z. Xiang, Growth Factor and Its Polymer Scaffold-Based Delivery System for Cartilage Tissue Engineering, *Int. J. Nanomed.*, 2020, **15**, 6097–6111.
- 120 Q. Zhou, B. Li, J. Zhao, W. Pan, J. Xu and S. Chen, IGF-I induces adipose derived mesenchymal cell chondrogenic differentiation in vitro and enhances chondrogenesis in vivo, *In vitro cellular & developmental biology, Animal*, 2016, **52**(3), 356–364.
- 121 C. Wen, L. Xu, X. Xu, D. Wang, Y. Liang and L. Duan, Insulin-like growth factor-1 in articular cartilage repair for osteoarthritis treatment, *Arthritis Res. Ther.*, 2021, **23**(1), 277.
- 122 A. M. Handorf and W. J. Li, Fibroblast growth factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis, *PLoS One*, 2011, **6**(7), 22887.
- 123 T. I. Morales, The quantitative and functional relation between insulin-like growth factor-I (IGF) and IGF-binding proteins during human osteoarthritis, *J. Orthop. Res.*, 2008, **26**(4), 465–474.
- 124 L. A. Fortier, J. U. Barker, E. J. Strauss, T. M. McCarrel and B. J. Cole, The role of growth factors in cartilage repair, *Clin. Orthop.*, 2011, **469**(10), 2706–2715.
- 125 M. B. Ellman, H. S. An, P. Muddasani and H. J. Im, Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis, *Gene*, 2008, **420**(1), 82–89.
- 126 I. Martin, G. Vunjak-Novakovic, J. Yang, R. Langer and L. E. Freed, Mammalian chondrocytes expanded in the



- presence of fibroblast growth factor 2 maintain the ability to differentiate and regenerate three-dimensional cartilaginous tissue, *Exp. Cell Res.*, 1999, **253**(2), 681–688.
- 127 D. Correa, R. A. Somoza, P. Lin, S. Greenberg, E. Rom, L. Duesler, *et al.*, Sequential exposure to fibroblast growth factors (FGF) 2, 9 and 18 enhances hMSC chondrogenic differentiation, *Osteoarthritis Cartilage*, 2015, **23**(3), 443–453.
- 128 L. A. Solchaga, K. Penick, V. M. Goldberg, A. I. Caplan and J. F. Welter, Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells, *Tissue engineering, Part A*, 2010, **16**(3), 1009–1019.
- 129 R. F. Loeser, S. Chubinskaya, C. Pacione and H. J. Im, Basic fibroblast growth factor inhibits the anabolic activity of insulin-like growth factor 1 and osteogenic protein 1 in adult human articular chondrocytes, *Arthritis Rheum.*, 2005, **52**(12), 3910–3917.
- 130 D. Yan, D. Chen and H. J. Im, Fibroblast growth factor-2 promotes catabolism via FGFR1-Ras-Raf-MEK1/2-ERK1/2 axis that coordinates with the PKCdelta pathway in human articular chondrocytes, *J. Cell. Biochem.*, 2012, **113**(9), 2856–2865.
- 131 K. Stewart, M. Pabbruwe, S. Dickinson, T. Sims, A. P. Hollander and J. B. Chaudhuri, The effect of growth factor treatment on meniscal chondrocyte proliferation and differentiation on polyglycolic acid scaffolds, *Tissue Eng.*, 2007, **13**(2), 271–280.
- 132 H. Maehara, S. Sotome, T. Yoshii, I. Torigoe, Y. Kawasaki, Y. Sugata, *et al.*, Repair of large osteochondral defects in rabbits using porous hydroxyapatite/collagen (HAp/Col) and fibroblast growth factor-2 (FGF-2), *J. Orthop. Res.*, 2010, **28**(5), 677–686.
- 133 K. Kieswetter, Z. Schwartz, M. Alderete, D. D. Dean and B. D. Boyan, Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation, *Endocrine*, 1997, **6**(3), 257–264.
- 134 B. Westermarck, L. Claesson-Welsh and C. H. Heldin, Structural and functional aspects of platelet-derived growth factor and its receptors, *Ciba Found. Symp.*, 1990, **150**, 6–14, 14–22.
- 135 S. R. Coughlin, M. A. Moskowitz, B. R. Zetter, H. N. Antoniades and L. Levine, Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor, *Nature*, 1980, **288**(5791), 600–602.
- 136 J. Fiedler, N. Etzel and R. E. Brenner, To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF, *J. Cell. Biochem.*, 2004, **93**(5), 990–998.
- 137 R. E. Toribio, H. A. Brown, C. M. Novince, B. Marlow, K. Herson, L. G. Lanigan, B. E. Hildreth III, J. L. Werbeck, S. T. Shu, G. Lorch, M. Carlton, J. Foley, P. Boyaka, L. K. McCauley and T. J. Rosol, The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice, *FASEB J.*, 2010, **24**(6), 1947–1957.
- 138 W. M. Philbrick, J. J. Wysolmerski, S. Galbraith, E. Holt, J. J. Orloff, K. H. Yang, *et al.*, Defining the roles of parathyroid hormone-related protein in normal physiology, *Physiol. Rev.*, 1996, **76**(1), 127–173.
- 139 M. A. Szychlinska, U. D'Amora, S. Ravalli, L. Ambrosio, M. Rosa and G. Musumeci, Functional Biomolecule Delivery Systems and Bioengineering in Cartilage Regeneration, *Curr. Pharm. Biotechnol.*, 2019, **20**(1), 32–46.
- 140 W. Zhang, J. Chen, S. Zhang and H. W. Ouyang, Inhibitory function of parathyroid hormone-related protein on chondrocyte hypertrophy: the implication for articular cartilage repair, *Arthritis Res. Ther.*, 2012, **14**(4), 221.
- 141 Y. J. Kim, H. J. Kim and G. I. Im, PTHrP promotes chondrogenesis and suppresses hypertrophy from both bone marrow-derived and adipose tissue-derived MSCs, *Biochem. Biophys. Res. Commun.*, 2008, **373**(1), 104–108.
- 142 T. F. Li, Y. Dong, A. M. Ionescu, R. N. Rosier, M. J. Zuscik, E. M. Schwarz, *et al.*, Parathyroid hormone-related peptide (PTHrP) inhibits Runx2 expression through the PKA signaling pathway, *Exp. Cell Res.*, 2004, **299**(1), 128–136.
- 143 B. Yu, X. Zhao, C. Yang, J. Crane, L. Xian, W. Lu, *et al.*, Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling, *J. Bone Miner. Res.*, 2012, **27**(9), 2001–2014.
- 144 A. Casado-Diaz, R. Santiago-Mora and J. M. Quesada, The N- and C-terminal domains of parathyroid hormone-related protein affect differently the osteogenic and adipogenic potential of human mesenchymal stem cells, *Exp. Mol. Med.*, 2010, **42**(2), 87–98.
- 145 X. Lin, P. O. Zamora, S. Albright, J. D. Glass and L. A. Peña, Multidomain synthetic peptide B2A2 synergistically enhances BMP-2 in vitro, *J. Bone Miner. Res.*, 2005, **20**(4), 693–703.
- 146 R. Li, J. Xu, D. S. H. Wong, J. Li, P. Zhao and L. Bian, Self-assembled N-cadherin mimetic peptide hydrogels promote the chondrogenesis of mesenchymal stem cells through inhibition of canonical Wnt/ β -catenin signaling, *Biomaterials*, 2017, **145**, 33–43.
- 147 X. Lv, C. Sun, B. Hu, S. Chen, Z. Wang, Q. Wu, *et al.*, Simultaneous Recruitment of Stem Cells and Chondrocytes Induced by a Functionalized Self-Assembling Peptide Hydrogel Improves Endogenous Cartilage Regeneration, *Front. Cell Dev. Biol.*, 2020, **8**, DOI: [10.3389/fcell.2020.00864](https://doi.org/10.3389/fcell.2020.00864).
- 148 A. Woods, G. Wang, H. Dupuis, Z. Shao and F. Beier, Rac1 signaling stimulates N-cadherin expression, mesenchymal condensation, and chondrogenesis, *J. Biol. Chem.*, 2007, **282**(32), 23500–23508.
- 149 L. Bian, M. Guvendiren, R. L. Mauck and J. A. Burdick, Hydrogels that mimic developmentally relevant matrix and N-cadherin interactions enhance MSC chondrogenesis, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**(25), 10117–10122.
- 150 J. Lu, X. Shen, X. Sun, H. Yin, S. Yang, C. Lu, *et al.*, Increased recruitment of endogenous stem cells and



- chondrogenic differentiation by a composite scaffold containing bone marrow homing peptide for cartilage regeneration, *Theranostics*, 2018, **8**(18), 5039–5058.
- 151 X. Guo, Q. Zheng, S. Yang, Z. Shao, Q. Yuan, Z. Pan, *et al.*, Repair of full-thickness articular cartilage defects by cultured mesenchymal stem cells transfected with the transforming growth factor beta1 gene, *Biomed. Mater.*, 2006, **1**(4), 206–215.
- 152 G. Kaul, M. Cucchiari, D. Arntzen, D. Zurakowski, M. D. Menger, D. Kohn, *et al.*, Local stimulation of articular cartilage repair by transplantation of encapsulated chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo, *J. Gene Med.*, 2006, **8**(1), 100–111.
- 153 S. Raisin, E. Belamie and M. Morille, Non-viral gene activated matrices for mesenchymal stem cells based tissue engineering of bone and cartilage, *Biomaterials*, 2016, **104**, 223–237.
- 154 O. Bleiziffer, E. Eriksson, F. Yao, R. E. Horch and U. Kneser, Gene transfer strategies in tissue engineering, *J. Cell. Mol. Med.*, 2007, **11**(2), 206–223.
- 155 G. Lisignoli, C. Manferdini, E. Lambertini, N. Zini, M. Angelozzi, E. Gabusi, *et al.*, Chondrogenic potential of Slug-depleted human mesenchymal stem cells, *Tissue Engineering, Part A*, 2014, **20**(19–20), 2795–2805.
- 156 S. Y. Jeon, J. S. Park, H. N. Yang, H. J. Lim, S. W. Yi, H. Park, *et al.*, Co-delivery of Cbfa-1-targeting siRNA and SOX9 protein using PLGA nanoparticles to induce chondrogenesis of human mesenchymal stem cells, *Biomaterials*, 2014, **35**(28), 8236–8248.
- 157 D. Guerit, J. M. Brondello, P. Chuchana, D. Philipot, K. Toupet, C. Bony, *et al.*, FOXO3A regulation by miRNA-29a Controls chondrogenic differentiation of mesenchymal stem cells and cartilage formation, *Stem Cells Dev.*, 2014, **23**(11), 1195–1205.
- 158 O. Ham, B. W. Song, S. Y. Lee, E. Choi, M. J. Cha, C. Y. Lee, *et al.*, The role of microRNA-23b in the differentiation of MSC into chondrocyte by targeting protein kinase A signaling, *Biomaterials*, 2012, **33**(18), 4500–4507.
- 159 S. Lv, J. Xu, L. Chen, H. Wu, W. Feng, Y. Zheng, *et al.*, MicroRNA-27b targets CBFB to inhibit differentiation of human bone marrow mesenchymal stem cells into hypertrophic chondrocytes, *Stem Cell Res. Ther.*, 2020, **11**(1), 392.
- 160 I. Uzieliene, U. Kalvaityte, E. Bernotiene and A. Mobasher, Non-viral Gene Therapy for Osteoarthritis, *Front. Bioeng. Biotechnol.*, 2020, **8**, 618399.
- 161 J. Xu, J. Li, S. Lin, T. Wu, H. Huang, K. Zhang, *et al.*, Nanocarrier-Mediated Codelivery of Small Molecular Drugs and siRNA to Enhance Chondrogenic Differentiation and Suppress Hypertrophy of Human Mesenchymal Stem Cells, *Adv. Funct. Mater.*, 2016, **26**(15), 2463–2472.
- 162 S. Wang, X. Wei, X. Sun, C. Chen, J. Zhou, G. Zhang, *et al.*, A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system, *Int. J. Nanomed.*, 2018, **13**, 617–631.
- 163 G. Gibson and H. Asahara, microRNAs and cartilage, *J. Orthop. Res.*, 2013, **31**(9), 1333–1344.
- 164 E. Hong and A. H. Reddi, MicroRNAs in chondrogenesis, articular cartilage, and osteoarthritis: implications for tissue engineering, *Tissue Eng., Part B*, 2012, **18**(6), 445–453.
- 165 H. Asahara, Current Status and Strategy of microRNA Research for Cartilage Development and Osteoarthritis Pathogenesis, *J. Bone Metab.*, 2016, **23**(3), 121–127.
- 166 L. Duan, Y. Liang, X. Xu, Y. Xiao and D. Wang, Recent progress on the role of miR-140 in cartilage matrix remodeling and its implications for osteoarthritis treatment, *Arthritis Res. Ther.*, 2020, **22**(1), 194.
- 167 Y. Sun and B. Qin, Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells, *Cancer Med.*, 2018, **7**(9), 4584–4597.
- 168 C. Li, Q. Hu, Z. Chen, B. Shen, J. Yang, P. Kang, *et al.*, MicroRNA-140 Suppresses Human Chondrocytes Hypertrophy by Targeting SMAD1 and Controlling the Bone Morphogenetic Protein Pathway in Osteoarthritis, *Am. J. Med. Sci.*, 2018, **355**(5), 477–487.
- 169 C. L. Murphy, B. L. Thoms, R. J. Vaghjiani and J. E. Lafont, Hypoxia. HIF-mediated articular chondrocyte function: prospects for cartilage repair, *Arthritis Res. Ther.*, 2009, **11**(1), 213.
- 170 H. H. Lee, C. C. Chang, M. J. Shieh, J. P. Wang, Y. T. Chen, T. H. Young, *et al.*, Hypoxia Enhances Chondrogenesis and Prevents Terminal Differentiation through PI3K/Akt/FoxO Dependent Anti-Apoptotic Effect, *Sci. Rep.*, 2013, **3**(1), 2683.
- 171 E. Duval, C. Baugé, R. Andriamanalijaona, H. Bénateau, S. Leclercq, S. Dutoit, *et al.*, Molecular mechanism of hypoxia-induced chondrogenesis and its application in in vivo cartilage tissue engineering, *Biomaterials*, 2012, **33**(26), 6042–6051.
- 172 N. Alijani, B. Johari, M. Moradi and M. Kadivar, A review on transcriptional regulation responses to hypoxia in mesenchymal stem cells, *Cell Biol. Int.*, 2020, **44**(1), 14–26.
- 173 A. Nowak-Stepniowska, P. N. Osuchowska, H. Fiedorowicz and E. A. Trafny, Insight in Hypoxia-Mimetic Agents as Potential Tools for Mesenchymal Stem Cell Priming in Regenerative Medicine, *Stem Cells Int.*, 2022, **2022**, 8775591.
- 174 D. K. Taheem, D. A. Foyt, S. Loaiza, S. A. Ferreira, D. Ilic, H. W. Auner, *et al.*, Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1 α Hydroxylase Inhibitors, *Stem Cells*, 2018, **36**(9), 1380–1392.
- 175 L. Chen, X. Huang, H. Chen, D. Bao, X. Su, L. Wei, *et al.*, Hypoxia-mimicking scaffolds with controlled release of DMOG and PTHrP to promote cartilage regeneration via the HIF-1 α /YAP signaling pathway, *Int. J. Biol. Macromol.*, 2023, **226**, 716–729.
- 176 K. Bajbouj, J. Shafarin and M. Hamad, High-Dose Deferoxamine Treatment Disrupts Intracellular Iron



- Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines, *Technol. Cancer Res. Treat.*, 2018, **17**, 1533033818764470.
- 177 C. Gao, W. Dai, X. Wang, L. Zhang, Y. Wang, Y. Huang, *et al.*, Magnesium Gradient-Based Hierarchical Scaffold for Dual-Lineage Regeneration of Osteochondral Defect, *Adv. Funct. Mater.*, 2023, **33**(43), 2304829.
- 178 J. Li and H. M. Wang, Effects of cobalt chloride on phenotypes of normal human saphenous vein smooth muscle cells, *Int. J. Clin. Exp. Med.*, 2014, **7**(12), 4933–4941.
- 179 S. Gao, J. Zhou, Y. Zhao, P. Toselli and W. Li, Hypoxia-response element (HRE)-directed transcriptional regulation of the rat lysyl oxidase gene in response to cobalt and cadmium, *Toxicol. Sci.*, 2013, **132**(2), 379–389.
- 180 S. Focaroli, G. Teti, V. Salvatore, I. Orienti and M. Falconi, Calcium/Cobalt Alginate Beads as Functional Scaffolds for Cartilage Tissue Engineering, *Stem Cells Int.*, 2016, **2016**, 2030478.
- 181 T. A. Holland, Y. Tabata and A. G. Mikos, Dual growth factor delivery from degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering, *J. Controlled Release*, 2005, **101**(1–3), 111–125.
- 182 A. Nalbadis, M. L. Trutschel, H. Lucas, J. Luetzkendorf, A. Meister and K. Mader, Selection and Incorporation of siRNA Carrying Non-Viral Vector for Sustained Delivery from Gellan Gum Hydrogels, *Pharmaceutics*, 2021, **13**(10), 1546.
- 183 C. E. Nelson, M. K. Gupta, E. J. Adolph, J. M. Shannon, S. A. Guelcher and C. L. Duvall, Sustained local delivery of siRNA from an injectable scaffold, *Biomaterials*, 2012, **33**(4), 1154–1161.
- 184 L. Zhou, L. E. Rubin, C. Liu and Y. Chen, Short interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases, *Regener. Eng. Transl. Med.*, 2020, **7**(3), 283–290.
- 185 M. Chen, S. Gao, M. Dong, J. Song, C. Yang, K. A. Howard, *et al.*, Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery, *ACS Nano*, 2012, **6**(6), 4835–4844.
- 186 J. Salvador, J. Berthelot, C. Bony, B. Robin, J. L. K. Him, D. Noël, *et al.*, Size-tunable lipid vectors for controlled local delivery of siRNA from gene activated matrix, *Acta Biomater.*, 2022, **153**, 97–107.
- 187 S. Yang, K. F. Leong, Z. Du and C. K. Chua, The design of scaffolds for use in tissue engineering, Part I. Tradit Factors, *Tissue Eng.*, 2001, **7**(6), 679–689.
- 188 D. Howard, L. D. Buttery, K. M. Shakesheff and S. J. Roberts, Tissue engineering: strategies, stem cells and scaffolds, *J. Anat.*, 2008, **213**(1), 66–72.
- 189 M. I. Echeverria Molina, K. G. Malollari and K. Komvopoulos, Design Challenges in Polymeric Scaffolds for Tissue Engineering, *Front. Bioeng. Biotechnol.*, 2021, **9**, DOI: [10.3389/fbioe.2021.617141](https://doi.org/10.3389/fbioe.2021.617141).
- 190 H. Zhang, L. Zhou and W. Zhang, Control of scaffold degradation in tissue engineering: a review, *Tissue Eng., Part B*, 2014, **20**(5), 492–502.
- 191 J. Chi, M. Wang, J. Chen, L. Hu, Z. Chen and L. J. Backman, *et al.*, *Topographic Orientation of Scaffolds for Tissue Regeneration: Recent Advances in Biomaterial Design and Applications*, Biomimetics, Basel, Switzerland, 2022, vol. 7.
- 192 H. Akkiraju and A. Nohe, Role of Chondrocytes in Cartilage Formation, Progression of Osteoarthritis and Cartilage Regeneration, *J. Dev. Biol.*, 2015, **3**(4), 177–192.
- 193 B. Li, F. Wang, F. Hu, T. Ding, P. Huang, X. Xu, *et al.*, Injectable “nano-micron” combined gene-hydrogel microspheres for local treatment of osteoarthritis, *NPG Asia Mater.*, 2022, **14**(1), 1.
- 194 H. Xiang, C. Zhang, Y. Xiong, Y. Wang, C. Pu, J. He, *et al.*, MMP13-responsive hydrogel microspheres for osteoarthritis treatment by precise delivery of celecoxib, *Mater. Des.*, 2024, **241**, 112966.
- 195 J. Ratanavaraporn, K. Soontornvipart, S. Shuangshoti, S. Shuangshoti and S. Damrongsakkul, Localized delivery of curcumin from injectable gelatin/Thai silk fibroin microspheres for anti-inflammatory treatment of osteoarthritis in a rat model, *Inflammopharmacology*, 2017, **25**(2), 211–221.
- 196 H. Liu, S. Wang and N. Qi, Controllable structure, properties, and degradation of the electrospun PLGA/PLA-blended nanofibrous scaffolds, *J. Appl. Polym. Sci.*, 2012, **125**(S2), 468–476.
- 197 Q. Zheng, Z. Chu, X. Li, H. Kang, X. Yang and Y. Fan, The Effect of Fluid Shear Stress on the In Vitro Release Kinetics of Sirolimus from PLGA Films, *Polymers*, 2017, **9**(11), 618.
- 198 T. Zhao, X. Li, H. Li, H. Deng, J. Li, Z. Yang, *et al.*, Advancing drug delivery to articular cartilage: From single to multiple strategies, *Acta Pharm. Sin. B*, 2023, **13**(10), 4127–4148.
- 199 J. H. Lee, P. Y. Kim, Y. C. Pyun, J. Park, T. W. Kang, J. S. Seo, *et al.*, Cartilage regeneration using transforming growth factor-beta 3-loaded injectable crosslinked hyaluronic acid hydrogel, *Biomater. Sci.*, 2024, **12**(2), 479–494.
- 200 X. Sun, J. Wang, Y. Wang, C. Huang, C. Yang, M. Chen, *et al.*, Scaffold with Orientated Microtubule Structure Containing Polylysine-Heparin Sodium Nanoparticles for the Controlled Release of TGF- β 1 in Cartilage Tissue Engineering, *ACS Appl. Bio Mater.*, 2018, **1**(6), 2030–2040.
- 201 C. Addi, F. Murschel and G. De Crescenzo, Design and Use of Chimeric Proteins Containing a Collagen-Binding Domain for Wound Healing and Bone Regeneration, *Tissue Eng., Part B*, 2017, **23**(2), 163–182.
- 202 N. Nishi, O. Matsushita, K. Yuube, H. Miyataka, A. Okabe and F. Wada, Collagen-binding growth factors: Production and characterization of functional fusion proteins having a collagen-binding domain, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**(12), 7018–7023.
- 203 X. C. Wu, B. O. Huang, J. Wang, C. Q. Li and Y. U. E. Zhou, Collagen-targeting parathyroid hormone-related peptide promotes collagen binding and in vitro



- chondrogenesis in bone marrow-derived MSCs, *Int. J. Mol. Med.*, 2013, **31**(2), 430–436.
- 204 T. Nakaji-Hirabayashi, K. Kato, Y. Arima and H. Iwata, Oriented immobilization of epidermal growth factor onto culture substrates for the selective expansion of neural stem cells, *Biomaterials*, 2007, **28**(24), 3517–3529.
- 205 K. S. Masters, Covalent Growth Factor Immobilization Strategies for Tissue Repair and Regeneration, *Macromol. Biosci.*, 2011, **11**(9), 1149–1163.
- 206 K. B. Seims, N. K. Hunt and L. W. Chow, Strategies to Control or Mimic Growth Factor Activity for Bone, Cartilage, and Osteochondral Tissue Engineering, *Bioconjugate Chem.*, 2021, **32**(5), 861–878.
- 207 D. Enriquez-Ochoa, P. Robles-Ovalle, K. Mayolo-Deloisa and M. E. G. Brunck, Immobilization of Growth Factors for Cell Therapy Manufacturing, *Front. Bioeng. Biotechnol.*, 2020, **8**, 620.
- 208 R. N. Shah, N. A. Shah, M. M. D. R. Lim, C. Hsieh, G. Nuber and S. I. Stupp, Supramolecular design of self-assembling nanofibers for cartilage regeneration, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**(8), 3293–3298.
- 209 J. Chen, Y. Li, B. Wang, J. Yang, B. C. Heng, Z. Yang, *et al.*, TGF- β 1 affinity peptides incorporated within a chitosan sponge scaffold can significantly enhance cartilage regeneration, *J. Mater. Chem. B*, 2018, **6**(4), 675–687.
- 210 J. A. Lewis, R. Freeman, J. K. Carrow, T. D. Clemons, L. C. Palmer and S. I. Stupp, Transforming Growth Factor β -1 Binding by Peptide Amphiphile Hydrogels, *ACS Biomater. Sci. Eng.*, 2020, **6**(8), 4551–4560.
- 211 M. Xiao, J. Xiao, G. Wu, Y. Ke, L. Fang, C. Deng, *et al.*, Anchoring TGF- β 1 on biomaterial surface via affinitive interactions: Effects on spatial structures and bioactivity, *Colloids Surf., B*, 2018, **166**, 254–261.
- 212 W. J. King and P. H. Krebsbach, Growth factor delivery: how surface interactions modulate release in vitro and in vivo, *Adv. Drug Delivery Rev.*, 2012, **64**(12), 1239–1256.
- 213 D. Hachim, T. E. Whittaker, H. Kim and M. M. Stevens, Glycosaminoglycan-based biomaterials for growth factor and cytokine delivery: Making the right choices, *J. Controlled Release*, 2019, **313**, 131–147.
- 214 Y. Liang and K. L. Kiick, Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications, *Acta Biomater.*, 2014, **10**(4), 1588–1600.
- 215 Y. K. Joung, J. W. Bae and K. D. Park, Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration, *Expert Opin. Drug Delivery*, 2008, **5**(11), 1173–1184.
- 216 A. Ori, M. C. Wilkinson and D. G. Fernig, The heparanome and regulation of cell function: structures, functions and challenges, *Front. Biosci.*, 2008, **13**, 4309–4338.
- 217 J. Fang, Y. Dong, N. Salamat-Miller and C. R. Middaugh, DB-PABP: a database of polyanion-binding proteins, *Nucleic Acids Res.*, 2008, **36**(Database issue), 303–306.
- 218 A. G. Bajpayee and A. J. Grodzinsky, Cartilage-targeting drug delivery: can electrostatic interactions help?, *Nature reviews, Rheumatology*, 2017, **13**(3), 183–193.
- 219 V. Adibnia, M. Mirbagheri, S. Salimi, G. Crescenzo and X. Banquy, Nonspecific interactions in biomedical applications, *Curr. Opin. Colloid Interface Sci.*, 2020, **47**, 70–83.
- 220 A. Ori, P. Free, J. Courty, M. C. Wilkinson and D. G. Fernig, Identification of heparin-binding sites in proteins by selective labeling, *Mol. Cell. Proteomics*, 2009, **8**(10), 2256–2265.
- 221 S. E. Sakiyama-Elbert and J. A. Hubbell, Development of fibrin derivatives for controlled release of heparin-binding growth factors, *J. Controlled Release*, 2000, **65**(3), 389–402.
- 222 M. Lyon, G. Rushton and J. T. Gallagher, The interaction of the transforming growth factor- β s with heparin/heparan sulfate is isoform-specific, *J. Biol. Chem.*, 1997, **272**(29), 18000–18006.
- 223 R. Jin, L. S. M. Teixeira, P. J. Dijkstra, C. A. Blitterswijk, M. Karperien and J. Feijen, Chondrogenesis in injectable enzymatically crosslinked heparin/dextran hydrogels, *J. Controlled Release*, 2011, **152**(1), 186–195.
- 224 G. C. J. Brown, K. S. Lim, B. L. Farrugia, G. J. Hooper and T. B. F. Woodfield, Covalent Incorporation of Heparin Improves Chondrogenesis in Photocurable Gelatin-Methacryloyl Hydrogels, *Macromol. Biosci.*, 2017, **17**, 1700158.
- 225 E. Hesse, U. Freudenberg, T. Niemiets, C. Greth, M. Weisser, S. Hagmann, *et al.*, Peptide-functionalized starPEG/heparin hydrogels direct mitogenicity, cell morphology and cartilage matrix distribution in vitro and in vivo, *J. Tissue Eng. Regener. Med.*, 2018, **12**(1), 229–239.
- 226 C. Levinson, M. Lee, L. A. Applegate and M. Zenobi-Wong, An injectable heparin-conjugated hyaluronan scaffold for local delivery of transforming growth factor β 1 promotes successful chondrogenesis, *Acta Biomater.*, 2019, **99**, 168–180.
- 227 M. Muller, E. Ozturk, O. Arlov, P. Gatenholm and M. Zenobi-Wong, Alginate Sulfate-Nanocellulose Bioinks for Cartilage Bioprinting Applications, *Ann. Biomed. Eng.*, 2017, **45**(1), 210–223.
- 228 R. Mhanna, A. Kashyap, G. Palazzolo, Q. Vallmajo-Martin, J. Becher, S. Moller, *et al.*, Chondrocyte culture in three dimensional alginate sulfate hydrogels promotes proliferation while maintaining expression of chondrogenic markers, *Tissue engineering, Part A*, 2014, **20**(9–10), 1454–1464.
- 229 O. Arlov and G. Skjak-Braek, Sulfated Alginates as Heparin Analogues: A Review of Chemical and Functional Properties, *Molecules*, 2017, **22**(5), 778.
- 230 M. Gionet-Gonzales, A. Casella, D. Diloretto, C. Ginnell, K. H. Griffin, A. Bigot, *et al.*, Sulfated Alginate Hydrogels Prolong the Therapeutic Potential of MSC Spheroids by Sequestering the Secretome, *Adv. Healthcare Mater.*, 2021, **10**(21), e2101048.
- 231 Ø. Arlov and G. Skjak-Braek, Sulfated Alginates as Heparin Analogues: A Review of Chemical and Functional Properties, *Molecules*, 2017, **22**(5), 778.
- 232 T. Re'em, Y. Kaminer-Israeli, E. Ruvinov and S. Cohen, Chondrogenesis of hMSC in affinity-bound TGF- β scaffolds, *Biomaterials*, 2012, **33**(3), 751–761.



- 233 M. Cucchiari and H. Madry, Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair, *Nature reviews, Rheumatology*, 2019, **15**(1), 18–29.
- 234 S. Elsler, S. Schetting, G. Schmitt, D. Kohn, H. Madry and M. Cucchiari, Effective, safe nonviral gene transfer to preserve the chondrogenic differentiation potential of human mesenchymal stem cells, *J. Gene Med.*, 2012, **14**(7), 501–511.
- 235 M. D. Krebs and E. Alsberg, Localized, targeted, and sustained siRNA delivery, *Chemistry*, 2011, **17**(11), 3054–3062.
- 236 M. Morille, T. Van-Thanh, X. Garric, J. Cayon, J. Coudane, D. Noël, *et al.*, New PLGA-P188-PLGA matrix enhances TGF- β 3 release from pharmacologically active microcarriers and promotes chondrogenesis of mesenchymal stem cells, *J. Controlled Release*, 2013, **170**(1), 99–110.
- 237 R. Budiraharjo, K. G. Neoh and E. T. Kang, Enhancing bioactivity of chitosan film for osteogenesis and wound healing by covalent immobilization of BMP-2 or FGF-2, *J. Biomater. Sci., Polym. Ed.*, 2013, **24**(6), 645–662.
- 238 Z. Wang, Z. Wang, W. W. Lu, W. Zhen, D. Yang and S. Peng, Novel biomaterial strategies for controlled growth factor delivery for biomedical applications, *NPG Asia Mater.*, 2017, **9**(10), 435–435.
- 239 C. H. Chou, W. T. Cheng, C. C. Lin, C. H. Chang, C. C. Tsai and F. H. Lin, TGF-beta1 immobilized tri-copolymer for articular cartilage tissue engineering, *J. Biomed. Mater. Res., Part B*, 2006, **77**(2), 338–348.
- 240 H. Fan, H. Tao, Y. Wu, Y. Hu, Y. Yan and Z. Luo, TGF-beta3 immobilized PLGA-gelatin/chondroitin sulfate/hyaluronic acid hybrid scaffold for cartilage regeneration, *J. Biomed. Mater. Res., Part A*, 2010, **95**(4), 982–992.
- 241 S. B. Gunnoo and A. Madder, Bioconjugation – using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers, *Org. Biomol. Chem.*, 2016, **14**(34), 8002–8013.
- 242 Z. Yang, F. Cao, H. Li, S. He, T. Zhao, H. Deng, *et al.*, Microenvironmentally optimized 3D-printed TGF β -functionalized scaffolds facilitate endogenous cartilage regeneration in sheep, *Acta Biomater.*, 2022, **150**, 181–198.
- 243 M. Motoyama, M. Deie, A. Kanaya, M. Nishimori, A. Miyamoto, S. Yanada, *et al.*, In vitro cartilage formation using TGF-beta-immobilized magnetic beads and mesenchymal stem cell-magnetic bead complexes under magnetic field conditions, *J. Biomed. Mater. Res., Part A*, 2010, **92**(1), 196–204.
- 244 M. L. Kang, J. Y. Ko, J. E. Kim and G. I. Im, Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration, *Biomaterials*, 2014, **35**(37), 9984–9994.
- 245 H. C. Kolb, M. G. Finn and K. B. Sharpless, Click Chemistry: Diverse Chemical Function from a Few Good Reactions, *Angew. Chem., Int. Ed.*, 2001, **40**(11), 2004–2021.
- 246 C. Barner-Kowollik, F. E. Prez, P. Espeel, C. J. Hawker, T. Junkers, H. Schlaad, *et al.*, Clicking” polymers or just efficient linking: what is the difference?, *Angew. Chem., Int. Ed.*, 2011, **50**(1), 60–62.
- 247 M. A. Azagarsamy and K. S. Anseth, Bioorthogonal Click Chemistry: An Indispensable Tool to Create Multifaceted Cell Culture Scaffolds, *ACS Macro Lett.*, 2013, **2**(1), 5–9.
- 248 E. S. Place, R. Nair, H. N. Chia, G. Szulgit, E. H. Lim and M. M. Stevens, Latent TGF-beta hydrogels for cartilage tissue engineering, *Adv. Healthcare Mater.*, 2012, **1**(4), 480–484.
- 249 J. D. McCall, J. E. Luoma and K. S. Anseth, Covalently tethered transforming growth factor beta in PEG hydrogels promotes chondrogenic differentiation of encapsulated human mesenchymal stem cells, *Drug Delivery Transl. Res.*, 2012, **2**(5), 305–312.
- 250 T. Bock, V. Schill, M. Krahnke, A. F. Steinert, J. Tessmar, T. Blunk, *et al.*, TGF-beta1-Modified Hyaluronic Acid/Poly (glycidol) Hydrogels for Chondrogenic Differentiation of Human Mesenchymal Stromal Cells, *Macromol. Biosci.*, 2018, **18**(7), 1700390.
- 251 S. H. Park, J. S. Kwon, B. S. Lee, J. H. Park, B. K. Lee, J. H. Yun, *et al.*, BMP2-modified injectable hydrogel for osteogenic differentiation of human periodontal ligament stem cells, *Sci. Rep.*, 2017, **7**(1), 6603.
- 252 M. Nouri-Felekori, N. Nezafati, M. Moraveji, S. Hesaraki and T. Ramezani, Bioorthogonal hydroxyethyl cellulose-based scaffold crosslinked via click chemistry for cartilage tissue engineering applications, *Int. J. Biol. Macromol.*, 2021, **183**, 2030–2043.
- 253 J. J. Patel, C. L. Flanagan and S. J. Hollister, Bone Morphogenetic Protein-2 Adsorption onto Poly- ϵ -caprolactone Better Preserves Bioactivity In Vitro and Produces More Bone In Vivo than Conjugation Under Clinically Relevant Loading Scenarios, *Tissue Eng., Part C*, 2015, **21**(5), 489–498.
- 254 H. Lee, S. Lim, M. S. Birajdar, S. H. Lee and H. Park, Fabrication of FGF-2 immobilized electrospun gelatin nanofibers for tissue engineering, *Int. J. Biol. Macromol.*, 2016, **93**(Pt B), 1559–1566.
- 255 E. K. Riga, J. S. Saar, R. Erath, M. Hechenbichler and K. Lienkamp, On the Limits of Benzophenone as Cross-Linker for Surface-Attached Polymer Hydrogels, *Polymers*, 2017, **9**(12), 686.
- 256 D. W. Ham, E. C. Jang, T. I. Son, T. J. Lee and K. S. Song, Photo-immobilization of bone morphogenetic protein-2 using azidophenyl gelatin on a collagen sheet enhances osteogenesis in a rat calvarial defect model, *J. Ind. Eng. Chem.*, 2016, **40**, 177–184.
- 257 C. D. Spicer and E. T. Pashuck, Achieving Control Biomol-Biomater Conjug, *Chem. Rev.*, 2018, **118**(16), 7702–7743.
- 258 J. H. Jeong, E. H. Kim, G. D. Han, J. W. Nah, Y. Ito and T. I. Son, BMP-2 immobilization by phosphonated UV-curable low-molecular-weight chitosan derivative on the surface of titanium, *J. Ind. Eng. Chem.*, 2016, **34**, 33–40.
- 259 J. M. Banks, L. C. Mozdzen, B. A. C. Harley and R. C. Bailey, The combined effects of matrix stiffness and growth factor immobilization on the bioactivity and differ-



- entiation capabilities of adipose-derived stem cells, *Biomaterials*, 2014, **35**(32), 8951–8959.
- 260 M. B. Schmidt, E. H. Chen and S. E. Lynch, A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair, *Osteoarthritis Cartilage*, 2006, **14**(5), 403–412.
- 261 J. Li, G. Chen, X. Xu, P. Abdou, Q. Jiang, D. Shi, *et al.*, Advances of injectable hydrogel-based scaffolds for cartilage regeneration, *Regener. Biomater.*, 2019, **6**(3), 129–140.
- 262 B. K. Mann, R. H. Schmedlen and J. L. West, Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells, *Biomaterials*, 2001, **22**(5), 439–444.
- 263 M. Liu, X. Zeng, C. Ma, H. Yi, Z. Ali, X. Mou, *et al.*, Injectable hydrogels for cartilage and bone tissue engineering, *Bone Res.*, 2017, **5**, 17014.
- 264 O. Wichterle and D. Lím, Hydrophilic Gels for Biological Use, *Nature*, 1960, **185**(4706), 117–118.
- 265 J. L. Drury and D. J. Mooney, Hydrogels for tissue engineering: scaffold design variables and applications, *Biomaterials*, 2003, **24**(24), 4337–4351.
- 266 H. Carrelo, P. I. P. Soares, J. P. Borges and M. T. Cidade, Injectable Composite Systems Based on Microparticles in Hydrogels for Bioactive Cargo Controlled Delivery, *Gels*, 2021, **7**(3), 147.
- 267 V. E. Santo, M. E. Gomes, J. F. Mano and R. L. Reis, Controlled release strategies for bone, cartilage, and osteochondral engineering—Part II: challenges on the evolution from single to multiple bioactive factor delivery, *Tissue Eng., Part B*, 2013, **19**(4), 327–352.
- 268 N. Butoescu, C. A. Seemayer, M. Foti, O. Jordan and E. Doelker, Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis, *Biomaterials*, 2009, **30**(9), 1772–1780.
- 269 E. Horisawa, K. Kubota, I. Tuboi, K. Sato, H. Yamamoto, H. Takeuchi, *et al.*, Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium, *Pharm. Res.*, 2002, **19**(2), 132–139.
- 270 J. M. Lu, X. Wang, C. Marin-Muller, H. Wang, P. H. Lin, Q. Yao, *et al.*, Current advances in research and clinical applications of PLGA-based nanotechnology, *Expert Rev. Mol. Diagn.*, 2009, **9**(4), 325–341.
- 271 W. Dai, Q. Liu, S. Li, Y. Gao, C. Feng, L. Guo, *et al.*, Functional injectable hydrogel with spatiotemporal sequential release for recruitment of endogenous stem cells and in situ cartilage regeneration, *J. Mater. Chem. B*, 2023, **11**(18), 4050–4064.
- 272 Y. Dong, Y. Liu, Y. Chen, X. Sun, L. Zhang, Z. Zhang, *et al.*, Spatiotemporal regulation of endogenous MSCs using a functional injectable hydrogel system for cartilage regeneration, *NPG Asia Mater.*, 2021, **13**(1), 71.
- 273 S. M. Lim, S. H. Oh, H. H. Lee, S. H. Yuk, G. I. Im and J. H. Lee, Dual growth factor-releasing nanoparticle/hydrogel system for cartilage tissue engineering, *J. Mater. Sci. Mater. Med.*, 2010, **21**(9), 2593–2600.
- 274 X. Ran, Q. Wang, Y. Sun, Q. Pan, H. Chen, W. Ren, *et al.*, Dual microparticles programmed delivery system regulating stem cell-based cartilage regeneration by cartilage-specific matrix hydrogels, *Composites, Part B*, 2024, **272**, 111221.
- 275 B. Wang, F. Chariyev-Prinz, R. Burdis, K. Eichholz and D. J. Kelly, Additive manufacturing of cartilage-mimetic scaffolds as off-the-shelf implants for joint regeneration, *Biofabrication*, 2022, **14**(2), 024101.
- 276 M. K. Gupta, F. Meng, B. N. Johnson, Y. L. Kong, L. Tian, Y. W. Yeh, *et al.*, 3D Printed Programmable Release Capsules, *Nano Lett.*, 2015, **15**(8), 5321–5329.
- 277 W. Zhu, H. Cui, B. Boualam, F. Masood, E. Flynn, R. D. Rao, *et al.*, 3D bioprinting mesenchymal stem cell-laden construct with core-shell nanospheres for cartilage tissue engineering, *Nanotechnology*, 2018, **29**(18), 185101.
- 278 G. A. Mannella, G. Conoscenti, F. Carfi Pavia, V. La Carrubba and V. Brucato, Preparation of polymeric foams with a pore size gradient via Thermally Induced Phase Separation (TIPS), *Mater. Lett.*, 2015, **160**, 31–33.
- 279 A. Prasad, M. R. Sankar and V. Katiyar, State of Art on Solvent Casting Particulate Leaching Method for Orthopedic Scaffolds Fabrication, *Mater. Today: Proc.*, 2017, **4**(2, Part A), 898–907.
- 280 T. V. Plisko, A. V. Penkova, K. S. Burts, A. V. Bilyukevich, M. E. Dmitrenko, G. B. Melnikova, *et al.*, Effect of Pluronic F127 on porous and dense membrane structure formation via non-solvent induced and evaporation induced phase separation, *J. Membr. Sci.*, 2019, **580**, 336–349.
- 281 Y. Chen, Z. Jia, M. Shafiq, X. Xie, X. Xiao, R. Castro, *et al.*, Gas foaming of electrospun poly(L-lactide-co-caprolactone)/silk fibroin nanofiber scaffolds to promote cellular infiltration and tissue regeneration, *Colloids Surf., B*, 2021, **201**, 111637.
- 282 A. F. Girão, Â. Semitela, G. Ramalho, A. Completo and P. A. A. P. Marques, Mimicking nature: Fabrication of 3D anisotropic electrospun polycaprolactone scaffolds for cartilage tissue engineering applications, *Composites, Part B*, 2018, **154**, 99–107.
- 283 Y. Zhou, J. Chyu and M. Zumwalt, Recent Progress of Fabrication of Cell Scaffold by Electrospinning Technique for Articular Cartilage Tissue Engineering, *Int. J. Biomater.*, 2018, **2018**, 1953636.
- 284 Â. Semitela, A. F. Girão, C. Fernandes, G. Ramalho, I. Bdikin, A. Completo, *et al.*, Electrospinning of bioactive polycaprolactone-gelatin nanofibres with increased pore size for cartilage tissue engineering applications, *J. Biomater. Appl.*, 2020, **35**(4–5), 471–484.
- 285 A. Eltom, G. Zhong and A. Muhammad, Scaffold Techniques and Designs in Tissue Engineering Functions and Purposes: A Review, *Adv. Mater. Sci. Eng.*, 2019, **2019**, e3429527.
- 286 J. Huang, J. Xiong, D. Wang, J. Zhang, L. Yang, S. Sun, *et al.*, 3D Bioprinting of Hydrogels for Cartilage Tissue Engineering, *Gels*, 2021, **7**(3), 144.



- 287 M. Li, D. Sun, J. Zhang, Y. Wang, Q. Wei and Y. Wang, Application and development of 3D bioprinting in cartilage tissue engineering, *Biomater. Sci.*, 2022, **10**(19), 5430–5458.
- 288 J. Zhou, Q. Li, Z. Tian, Q. Yao and M. Zhang, Recent advances in 3D bioprinted cartilage-mimicking constructs for applications in tissue engineering, *Mater. Today Bio*, 2023, **23**, 100870.
- 289 P. Baei, H. Daemi, F. Mostafaei, F. A. Sayahpour, H. Baharvand and M. B. Eslaminejad, A tough polysaccharide-based cell-laden double-network hydrogel promotes articular cartilage tissue regeneration in rabbits, *Chem. Eng. J.*, 2021, **418**, 129277.
- 290 X. Xu, Y. J. Liang, X. F. Li, K. Ouyang, M. Y. Wang, T. Cao, *et al.*, Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration, *Biomaterials*, 2021, **269**, 120539.
- 291 C. Y. Chen, C. C. Li, C. J. Ke, J. S. Sun and F. H. Lin, Kartogenin Enhances Chondrogenic Differentiation of MSCs in 3D Tri-Copolymer Scaffolds and the Self-Designed Bioreactor System, *Biomolecules*, 2021, **11**(1), 115.
- 292 M. Rezvaninia, N. Baheiraei and F. Bagheri, Effects of kartogenin/PLGA nanoparticles on silk scaffold properties and stem cell fate, *Bioinspired, Biomimetic Nanobiomater.*, 2021, **10**(2), 45–53.
- 293 J. J. Wei, P. Ran, Q. Y. Li, J. F. Lu, L. Zhao, Y. Liu, *et al.*, Hierarchically structured injectable hydrogels with loaded cell spheroids for cartilage repairing and osteoarthritis treatment, *Chem. Eng. J.*, 2022, **430**, 132211.
- 294 M. S. Bozhokin, S. A. Bozhkova, G. I. Netylko, D. G. Nakonechny, Y. A. Nashchekina, M. I. Blinova, *et al.*, Experimental Replacement of the Surface Defect of Rat Hyaline Cartilage by a Cell-Engineered Construct, *Regener. Eng. Transl. Med.*, 2021, **7**(2), 184–193.
- 295 B. Wang, P. J. Diaz-Payno, D. C. Browe, F. E. Freeman, J. Nulty, R. Burdis, *et al.*, Affinity-bound growth factor within sulfated interpenetrating network bioinks for bioprinting cartilaginous tissues, *Acta Biomater.*, 2021, **128**, 130–142.
- 296 A. B. Bello, Y. Kim, S. Park, M. S. Muttigi, J. Kim, H. Park, *et al.*, Matrilin3/TGF beta 3 gelatin microparticles promote chondrogenesis, prevent hypertrophy, and induce paracrine release in MSC spheroid for disc regeneration, *npj Regener. Med.*, 2021, **6**(1), 50.
- 297 E. P. Lamparelli, J. Lovecchio, M. C. Ciardulli, V. Giudice, T. P. Dale, C. Selleri, *et al.*, Della Porta. Chondrogenic Commit Hum Bone Marrow Mesenchymal Stem Cells Perfus Collagen Hydrogel Funct HTGF-Beta 1-Releas PLGA Microcarrier, *Pharmaceutics*, 2021, **13**(3), 399.
- 298 M. H. Hagmeijer, J. V. Korpershoek, J. F. Crispim, L. T. Chen, P. Jonkheijm, A. J. Krych, *et al.*, The regenerative effect of different growth factors and platelet lysate on meniscus cells and mesenchymal stromal cells and proof of concept with a functionalized meniscus implant, *J. Tissue Eng. Regener. Med.*, 2021, **15**(7), 648–659.
- 299 M. Knippenberg, M. N. Helder, B. Z. Doulabi, P. I. Wuisman and J. Klein-Nulend, Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells, *Biochem. Biophys. Res. Commun.*, 2006, **342**(3), 902–908.
- 300 S. Claus, E. Aubert-Foucher, M. Demoor, B. Camuzeaux, A. Paumier, M. Piperno, *et al.*, Chronic exposure of bone morphogenetic protein-2 favors chondrogenic expression in human articular chondrocytes amplified in monolayer cultures, *J. Cell. Biochem.*, 2010, **111**(6), 1642–1651.
- 301 I. Sekiya, D. C. Colter and D. J. Prockop, BMP-6 enhances chondrogenesis in a subpopulation of human marrow stromal cells, *Biochem. Biophys. Res. Commun.*, 2001, **284**(2), 411–418.
- 302 B. T. Estes, A. W. Wu and F. Guilak, Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6, *Arthritis Rheum.*, 2006, **54**(4), 1222–1232.
- 303 Y. Z. Jiang, Y. Y. Qi, X. H. Zou, L. L. Wang and H. W. Ouyang, *Comparison the Effects of BMP-4 and BMP-7 on Articular Cartilage Repair with Bone Marrow Mesenchymal Stem Cells*, Springer, Berlin, Heidelberg, 2009.
- 304 M. M. Caron, P. J. Emans, A. Cremers, D. A. Surtel, M. M. Coolen, L. W. Rhijn, *et al.*, Hypertrophic differentiation during chondrogenic differentiation of progenitor cells is stimulated by BMP-2 but suppressed by BMP-7, *Osteoarthritis Cartilage*, 2013, **21**(4), 604–613.
- 305 C. Betsholtz, M. Nistér, F. Rorsman, C. H. Heldin and B. Westermark, Structural and functional aspects of platelet-derived growth factor and its role in the pathogenesis of glioblastoma, *Mol. Chem. Neuropathol.*, 1989, **10**(1), 27–36.
- 306 M. Uomizu, T. Muneta, M. Ojima, I. Sekiya, H. Koga and K. Tsuji, PDGF-induced proliferation and differentiation of synovial mesenchymal stem cells is mediated by the PI3K-PKB/Akt pathway, *J. Med. Dent. Sci.*, 2018, **65**, 73–82.
- 307 M. Anderson-Baron, Y. Liang, M. Kunze, A. Mulet-Sierra, M. Osswald, K. Ansari, *et al.*, Suppression of Hypertrophy During in vitro Chondrogenesis of Cocultures of Human Mesenchymal Stem Cells and Nasal Chondrocytes Correlates With Lack of in vivo Calcification and Vascular Invasion, *Front. Bioeng. Biotechnol.*, 2021, **8**, DOI: [10.3389/fbioe.2020.572356](https://doi.org/10.3389/fbioe.2020.572356).
- 308 L. Y. Chan, C. C. Chang, P. L. Lai, T. Maeda, H. C. Hsu, C. Y. Lin, *et al.*, Cre/LoxP Genetic Recombination Sustains Cartilage Anabolic Factor Expression in Hyaluronan Encapsulated MSCs Alleviates Intervertebral Disc Degeneration, *Biomedicines*, 2022, **10**(3), 555.
- 309 D. J. Vail, R. A. Somoza and A. I. Caplan, MicroRNA Regulation of Bone Marrow Mesenchymal Stem Cell Chondrogenesis: Toward Articular Cartilage, *Tissue Eng., Part A*, 2022, **28**(5–6), 254–269.
- 310 T. Gómez-Leduc, M. Desancé, M. Hervieu, F. Legendre, D. Ollitrault, C. De Vienne, *et al.*, Hypoxia Is a Critical Parameter for Chondrogenic Differentiation of Human Umbilical Cord Blood Mesenchymal Stem Cells in Type I/III Collagen Sponges, *Int. J. Mol. Sci.*, 2017, **18**(9), 1933.

